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ABSTRACT 
 
HANN-HSIANG CHAO: Examination of the BRCA1-Dependent DNA Repair Pathway 
in Basal-like Breast Cancer 
(Under the direction of Dr. Charles Perou) 
 
Human breast cancer is a diverse disease, exhibiting variety in morphology, 
natural history, and therapeutic response.  Multiple studies have shown that breast 
tumors can be segregated into distinct subtypes, characterized by similarities in the 
genes they express.  One subtype, called basal-like breast tumors (BBT), represents 
10-20% of breast cancer diagnoses and is typically associated with poor outcomes.  
Our work has shown that BBT occurs with significantly higher frequency in women 
with germline mutations in breast cancer 1 (BRCA1).  Given the link between 
BRCA1-germline mutations and BBT, we proposed to determine whether the 
BRCA1-dependent DNA repair pathway is deficient during sporadic BBT formation.   
Our initial step was to identify BBT specific regions of aberration and 
determine if they affected important genetic pathways.  One region located on 
chromosome 5q contained multiple BRCA1-dependent repair pathway genes.  These 
genes exhibited frequent co-associated loss with each other and with other cancer 
relevant genes.  Exogenous disruption of these genes in normal breast epithelial cell 
lines increased sensitivity to DNA damage and impaired BRCA1 localization and 
function. 
We further characterized the genomic instability aspect of BBT by examining 
a previously undetectable form of genomic aberration we termed micro-
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aberrations.  These small-scale genomic changes (<5kb in some cases) are 
detectable using a high-resolution tiling array. We found these events were 
functional, relevant for survival, preferentially located in the promoter regions of 
cell cycle genes, and appear most frequently in BBT. 
Lastly, we examined BBT-specific loss of the tumor suppressor INPP4B.  We 
found that DNA, RNA, and protein expression of INPP4B are highly correlated with 
BBT and that it functions as an excellent marker of this subtype as well as predicting 
survival and response to therapy. 
It is critical to gain a greater understanding of BBT function as BBT poses a 
significant challenge to the US health care system; if BBT were to be treated as a 
unique disease separate from other breast cancers, it would represent the fourth 
leading cause of cancer deaths among women.  My work here describes newly 
discovered functional basal-specific aberrations that explain much of the biology of 
BBT. 
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CHAPTER ONE 
INTRODUCTION 
 
 
1.1  General Introduction 
Background 
Breast cancer affects approximately one in seven women worldwide and is 
the second leading cause of cancer deaths.  In recent years, the incidence of breast 
cancer has risen, owing to a combination of better awareness of the disease, more 
frequent screenings, and increased longevity.  However, over this same time period, 
overall mortality has decreased thanks to early detection and improvements in 
patient care.  Targeted therapies are a major advancement in the treatment of this 
disease, such as the use of selective estrogen receptor modulators, e.g. tamoxifen, 
and drugs that reduce circulating estrogen, e.g. aromatase inhibitors, in patients that 
have estrogen receptor positive disease.  Another example of targeted therapy 
comes in the form of trastuzumab, which is a monoclonal antibody utilized against 
HER2 receptor positive breast cancer.  Nonetheless, there still remains a significant 
portion of breast cancers that are unable to be treated by targeted therapy and must 
be managed by cytotoxic chemotherapy, which is associated with many adverse side 
effects.  Despite current treatment advances, approximately 40,000 women were 
estimated to die of breast cancer in 2011 in the United States, indicating that 
additional studies to improve therapy are still needed. 
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One class of breast cancer in particular, the basal-like breast tumors (BBT), 
are currently devoid of targeted therapies due to a lack expression of the three 
current biomarkers for breast cancer that guide therapy, namely the estrogen 
receptor, progesterone receptor, and the growth factor receptor HER2/ERBB2.  My 
research is focused on this subtype of breast cancer, specifically identifying regions 
of genomic instability within these tumors that may identify potential targets to 
develop for therapy.  By expanding our understanding of the factors that lead to the 
progression of this disease, we hope to identify unique characteristics that can be 
exploited for both better disease prediction and patient treatment. 
Normal Breast Development 
 In order to understand mammary carcinogenesis, one must first understand 
the normal development of mammary tissue.  Normal human breast tissue is very 
diverse, with an architecture comprised of many different cell types, that also 
undergoes dramatic changes in shape, size, and function throughout a woman’s 
lifetime (Howard and Gusterson 2000; Russo and Russo 2004). This diversity in 
mammary cells and their constant state of change contributes to the development of 
different types of breast tumors. 
The mammary gland first develops prenatally as rudimentary duct structures 
that have two layers of epithelial cells, the basement membrane and the stromal 
layer (Wiseman and Werb 2002).  At birth, the infant breast consists of a primitive, 
blunt-ended, ductal system comprised of one or two inner layers of luminal 
(epithelial) cells, and one layer of myoepithelial cells surrounding the lumen (Russo 
and Russo 2004).  After birth, the mammary gland is no longer subject to maternal 
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hormones, and undergoes differentiation and involution, eventually leaving small 
tubular structures surrounded by fibroblastic stroma (Anbazhagan et al. 1991).  
 With the onset of puberty, the rudimentary duct structures elongate and 
branch, resulting in the terminal duct lobular units, the site of future β-casein 
(milk)-producing cells,  or “alveolar buds" (Villadsen 2005). There is also a dramatic 
increase in stromal fat and fibroblastic tissue.  Once adulthood is reached, the 
mammary gland is comprised of a main lactiferous duct attached to the nipple that 
branches into 15-25 milk ducts, which further branch into many sub-segmental 
ducts. Different cell types, luminal and myoepithelial, constitute the gland and these 
can be distinguished morphologically and through histological stains (Figure 1.1).  
The gland is constantly influenced by hormones, with each ovulation promoting a 
small amount of additional budding. 
 With pregnancy, a massive increase in proliferation and formation of acini in 
the alveolar buds occurs (Villadsen et al. 2007). After birth, milk is secreted by the 
alveolar cells, which flows through the ducts to the nipple. Once lactation is 
complete, the acini (clusters of milk-producing lobules) involute through a period of 
apoptosis (Schorr et al. 1999; Strange et al. 2001). Lastly, post menopause, the 
number of both ducts and lobules are reduced through involution (Howard and 
Gusterson 2000).  
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1.2  Breast Cancer Molecular Subtypes and Outcome 
Overview 
Breast cancer has been shown to be not a single disease, but instead is a very 
heterogeneous disease with a spectrum of distinct cellular origins, somatic changes, 
and etiologies.  Over the years, clinical decision has expanded beyond factors such 
as stage, grade, and hormone receptor status to include the use of gene expression 
predictors as well (Fan et al. 2006).  DNA microarray analyses have now shown 
repeatedly that breast cancer is composed of at least six distinct tumor subtypes, 
potentially arising from different cell lineages (Prat et al. ; Perou et al. 2000; Sorlie 
et al. 2001; Sorlie et al. 2003; Hu et al. 2006). These include luminal A, luminal B, 
normal breast-like, HER2-enriched, claudin-low, and basal-like subtypes. Each 
subtype has a unique gene expression profile that reflects the biology of the breast 
tumor and also predicts patient clinical outcomes (Figure 1.2 and Figure 1.3). 
Estrogen Receptor-Positive Subtypes 
The majority of breast cancer patients (60-80%) present with 
luminal/estrogen-receptor-alpha positive  (ER+) tumors (luminal A and luminal B) 
(Perou et al. 2000). Although some luminal tumors are non-responsive or become 
resistant to therapy, they are typically excellent candidates for targeted endocrine 
therapies such as Tamoxifen, an estrogen receptor antagonist (Paik et al. 2004).  
Luminal A tumors are the most frequent (35-45%) and both luminal subtypes are 
characterized by the expression of transcription factors that include ER, GATA3, 
FOXA1 and XBP1 (Perou et al. 2000; Gruvberger et al. 2001; Sotiriou et al. 2002; van 
't Veer et al. 2002; Huang et al. 2003).  Luminal B tumors can be distinguished from 
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luminal A tumors through the “proliferation” signature (Perou et al. 1999; Whitfield 
et al. 2002), which is high in LumB tumors. The normal breast-like group also 
clusters with the ER-positive subtype and has a gene expression signature similar to 
that of normal breast.  This group is usually comprised of true normal breast 
samples and a few tumors, and studies suggest that in most cases this classification 
is due to a high amount of contaminating normal breast tissue (Hu et al. 2006).  
Estrogen Receptor-Negative Subtypes 
In contrast to the estrogen receptor positive subtypes are the ER-negative 
tumors, which are comprised of the HER2-enriched, Basal-like breast tumors, and 
claudin-low tumors.  Basal-like breast tumors will be described separately as they 
are the focus of this dissertation research.  The large majority of ER-negative tumors 
are represented by the HER2-enriched and BBT subtypes.  The HER2-enriched 
subtype is characterized by the high expression of HER2 and other genes on the 
HER2 amplicon (Pollack et al. 1999; Pollack et al. 2002).  The HER2-enriched 
subtype classification is noteworthy because of the development of trastuzumab, 
which is a biologically-directed therapy that targets HER2 (Goldenberg 1999; Burris 
2001; Slamon et al. 2001).  Another ER-negative subtype is the recently discovered 
claudin-low subtype (Prat et al.).  This relatively small subset of breast tumors (5%) 
is characterized by the lack of expression of tight junction and cell-cell adhesion 
proteins including Claudins 3, 4 and 7, occludin, and E-cadherin (Herschkowitz et al. 
2007).  Like basal-like breast tumors, which will be discussed below, these tumors 
are pathologically ER-negative, PR-negative, and HER2-not amplified, features 
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which make these “Triple-Negative” tumors; however, by expression they are a 
distinct subtype from basal-like breast tumors (Figure 1.2). 
Basal-like Breast Tumors 
In contrast to the luminal breast tumors are basal-like breast tumors, which 
are the focus of this work.  BBT account for 10-20% of all breast cancers and are 
often clinically labeled “triple negative”. BBT clearly poses a significant challenge to 
the US health care system, as evidenced by the fact that if BBT were to be treated as 
a unique disease separate from other breast cancers, it would represent the fourth 
leading cause of cancer deaths among women (Carey et al. 2006).  These tumors do 
not express ER-alpha, PR, and HER2, have limited treatment options, and patients 
typically experience poor outcomes (Sorlie et al. 2001; Sorlie et al. 2003; Nielsen et 
al. 2004; Paik et al. 2004).  They often exhibit high expression of cytokeratins 5 and 
17, cell surface markers expressed in normal mammary basal/myoepithelial cells, 
and a transcriptional signature similar to skin basal epithelial cells. It is believed 
however, that this tumor type is derived from luminal epithelium and not 
myoepithelium (Sauer 2007).  In addition, BBT also have high expression of the 
proliferation gene signature.  It has also been shown that BBT were significantly 
more frequent in African Americans versus Caucasians and it has been seen in 
population based studies that BBT display a unique set of risk factors that are 
sometimes the opposite in effect of these same risk factors in ER+/Luminal tumors 
(Carey et al. 2006).  Indeed, in the Carolina Breast Cancer Study, pregnancy was 
shown to be associated with an increased susceptibility to develop BBT, with 
increasing parity and younger age at first full term pregnancy also increasing risk, 
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which is the opposite of what is observed for luminal A tumors.  Lack of 
breastfeeding was another risk factor for basal-like breast cancer, suggesting there 
are protective effects of lactation (Carey et al. 2006). BBT also occurs with 
significantly higher frequency in women with germline mutations in the breast 
cancer 1 gene (BRCA1) (Foulkes et al. 2003; Sorlie et al. 2003; Arnes et al. 2005), 
thus suggesting possible genetic susceptibilities as well. 
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1.3  Genetic Changes in Breast Cancer 
Patterns of Genomic Instability in Breast Cancer Subtypes 
A hallmark of many human cancers is genomic instability and cancer can be 
thought of as the result of aneuploidy.  Specific patterns of copy number aberrations 
(CNA) can define genetic events associated with different breast cancer subtypes 
(Figure 1.4). Array comparative genome hybridization (aCGH) studies of tumor copy 
number states have demonstrated that tumors with similar gene expression 
subtypes may also share similar DNA Copy Number Aberrations (Russnes et al. ; 
Bergamaschi et al. 2006; Chin et al. 2006; Wood et al. 2007; Van Loo et al. 2010) and 
that CNA can be used to further sub-divide expression classes (Russnes et al.).  In 
some cases, tumors have single gene-specific amplicons occurring in a large 
percentage of cases, such as amplification of ERBB2 in 25-30% of breast tumors 
(Kauraniemi et al. 2004).  In these cases, treatment options (e.g. trastuzumab) 
attacking the aberrant gene offers a positive response (Goldenberg 1999; Burris 
2001).  The luminal A tumors are notable for their distinct lack of genomic 
instability, often showing aberrations only in chromosome 1q and 16q (Figure 
1.4B).  In fact, they can be distinguished from luminal B tumors through the higher 
levels of genomic instability displayed by luminal B tumors (Figure 1.4C).  The 
inherent heterogeneity of tumors is likely to demonstrate that the biological impact 
of several distinct CNA events initiates tumorigenesis through disruption of genes in 
specific pathways that are linked to specific cell types. 
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Basal-like Breast Tumor Genomic Alterations 
Nowhere is the case of genomic instability-driven tumorigenesis more 
prevalent than in the Basal-like subtype, where the majority of its tumor genome 
exhibits aberrant copy number states (Ding et al. ; Russnes et al. ; Bergamaschi et al. 
2006; Chin et al. 2006; Van Loo et al. 2010) (Figure 1.4a). Identifying the genes that 
contribute to this instability phenotype could be useful not only from a biological 
perspective, but also possibly as a clinical predictor of response. Previous studies 
(Loo et al. 2004; Bergamaschi 2006; Chin et al. 2006) have shown that BBT has 
greater genetic complexity compared to the other breast cancer subtypes (Figure 
1.4).   
Initial analyses of genetic and gene expression data indicate that various 
genomic regions are preferentially lost in BBT, suggesting that BBT is a unique 
entity not only on an expression level, but on a copy number level as well.  Many 
interesting genes are found in these basal-specific regions encompassing a number 
of important cellular pathways.  INPP4B is one gene that is specifically deleted in 
BBT and this gene has been shown to be a key player in the PI3K signaling pathway 
which is involved in controlling proliferation, cell survival, and genomic instability, 
among other functions (Fedele et al. ; Puc et al. 2005; Saal et al. 2005; Janzen and 
Scadden 2006; Baker 2007; Gewinner et al. 2009).   Interestingly, some of these 
regions also contain genes involved specifically in the BRCA1-pathway or more 
generally in DNA repair.  One hypothesis is that in a given BBT, a general deficiency 
in DNA repair occurs that can arise from deletion(s) in a subset of genes in the 
BRCA1/DNA repair pathway, such that different regions may be affected in different 
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tumors, but all affect the same pathway. This deficiency combined with ambient 
radiation damage or other mutagenic insults may induce BBT formation.  BBT may 
be particularly prone to chromosomal instability, due to the fact that alterations in 
DNA repair genes/proteins likely contribute to its formation. 
Despite the poor prognosis generally associated with BBTs, they are often 
initially responsive to chemotherapy treatments (Rouzier et al. 2005; Carey et al. 
2007). Our explanation for this sensitivity is the proposed DNA repair deficiency in 
BBT caused by aberrations in BRCA1 and/or other DNA repair proteins, coupled 
with their loss of RB and TP53 function (Troester et al. 2006; Herschkowitz et al. 
2008). In light of the association with BRCA1, this suggests a possible defect in 
double strand DNA break repair mechanisms, and some evidence of this is seen in 
the fact that basal-like tumor cell lines are more susceptible to DNA damaging 
agents as compared to normal human mammary epithelial cell lines (Figure 1.5).  
Analyses using an Illumina SNP microarray platform identified numerous 
regions of copy number loss that were statistically correlated only with BBT, 
including 5q11-35, 13q12-34, 14q11-32, 15q11-26, 17q12-23, and the X-
chromosome. Many of the genes mapped to these regions are part of the BRCA1-
pathway and are necessary for DNA repair. Examples include RAD17 (5q12), RAD50 
(5q23), RAP80 (5q35), RAD51 (15q15), RAD51B (14q12), RAD51C (17q23), and 
BRIP1 (17q23). It is also worth noting that a BRCA1-modifier locus for hereditary 
breast cancer penetrance has been mapped to the 5q region (Nathanson et al. 2002). 
In addition, when examining the BRCA1-pathway on a gene expression level, the 
average expression of these highlighted genes is also found to be lowest in the basal-
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like subtype (Figure 1.6).   It stands to reason that there could be gene-environment 
interactions in these candidate genes in the form of germline variants associated 
with susceptibility to BBT.  It is our hypothesis that sporadic BBTs do not 
necessarily have a defect in BRCA1 itself, but instead they may have a general defect 
in double strand DNA break repair caused by the sporadic loss of one or more DNA 
repair pathway genes. 
There is some evidence suggesting that there is a coordinated loss of this 
specific pathway as many of the genes are highly co-correlated with respect to their 
CNA; for example RAD17, RAD50, RAD51, RAD51L1, and RASGRF1 are often lost 
together in sporadic BBT.  This finding can partly be explained by the fact that many 
of these genes are neighbors and found on the same chromosomal arm, but this is 
not universally the case.  RAD17 and RAD50 are both on the 5q arm and have the 
highest concordance of loss, but RAD51 and RASGRF1 are located on a separate 
chromosome, on the 15q arm.  On average, it appears that more than one repair 
gene is lost in a given BBT.  Discovering other gene associations and the biology 
behind them should give insight into the etiology of these tumors.  
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1.4  The Role of BRCA1 in Breast Cancer  
BRCA1 Function and Association with Basal-like Breast cancer 
As previously mentioned, one clue in identifying BBT causative events was 
the discovery of an association between BBT and BRCA1 (Sorlie et al. 2003). BRCA1 
is an ubiquitous tumor suppressor that has functions in the nucleus in transcription, 
gene silencing, chromatin remodeling, and several DNA repair mechanisms (Starita 
and Parvin 2003). It has been shown to be essential for normal development as 
BRCA1 knockout mice show early embryonic lethality (Brodie and Deng 2001). In 
addition, BRCA1 is thought to be a guardian of genomic stability because of its 
involvement in the cellular response pathway to DNA double-strand breaks (DSB) 
(Venkitaraman 2002). Mouse and human cells deficient for BRCA1 are sensitive to 
ionizing radiation (IR), indicating a role in DNA DSB repair (Deng and Wang 2003). 
Surprisingly, although human BRCA1 mutation carriers develop BBT around 80% of 
the time, the BRCA1 gene/protein is shown to be normal in the great majority of 
sporadic BBT (>90%) (Richardson et al. 2006) and there is also, at present, no 
proven correlation between BRCA1 methylation and BBT (Matros et al. 2005; 
Richardson et al. 2006; Turner et al. 2006). Overall, little conclusive data exists 
concerning BRCA1-pathway function in sporadic BBT.  We hypothesized that defects 
in other members of the BRCA1-pathway, rather than disruption of BRCA1 itself, 
may contribute to sporadic BBT formation. 
BRCA1 DNA Repair Pathway 
 A number of BRCA1 DNA repair pathway members were shown to be 
associated with BBT and have low gene expression within the subtype, including 
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RAP80, RAD50, RAD17, RAD51B, and RAD51C (Figure 1.6).  RAP80 physically binds to 
BRCA1 and is required for the localization of BRCA1 to DNA-repair foci (Kim et al. 
2007; Sobhian et al. 2007; Wang et al. 2007).  RAD50 is part of a BRCA1-associated 
genome surveillance complex/BASC that is involved in BRCA1-dependent DNA 
repair (Zhong et al. 1999; Wang et al. 2000).  RAD17 is phosphorylated by ATM/ATR 
in response to DNA damage (Rauen et al. 2000; Bao et al. 2001; Roos-Mattjus et al. 
2002; Post et al. 2003).  RAD51C is thought to be involved in homologous 
recombination mediated repair pathway (HR) of double-strand breaks and is part of 
a complex of DNA repair proteins (Dosanjh et al. 1998; Miller et al. 2002; French et 
al. 2003).  RAD51B, also known as RAD51L1, is also thought to be involved in HR 
(Takata et al. 2000; Miller et al. 2002).  Furthermore, haplo-insufficiency of RAD51B 
has been shown to lead to centrosome fragmentation, aneuploidy, and 
hypersensitivity to DNA-damaging agents (Takata et al. 2000; Miller et al. 2002; 
Date et al. 2006), of which the latter two are hallmarks of BBT. 
 Many studies have been performed focused on the link between BRCA1 and 
breast cancer, but a broader analysis of the BRCA1 pathway as a whole has 
heretofore been lacking.  A more far-reaching analysis looking at the component 
genes within the basal-like subtype may have the ability to uncover findings that 
have previously been masked either by examining all breast cancers as a 
homogenous entity, or using BRCA1 alone as the readout of a functioning repair 
pathway, when in fact many other disruptions can occur leading to the same result. 
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1.5  Research Introduction 
This work will examine the contribution of the BRCA1-dependent DNA repair 
pathway and genomic instability to the initiation and progression of BBT, a breast 
cancer subtype with poor prognosis.  My aim is to elucidate how the response to 
DNA damage contributes to the formation of some breast cancers and to investigate 
the role of BRCA1 pathway function in sporadic BBT.  In addition, the data 
generated will provide information that will aid in the systematic classification of 
this complex tumor subtype.  More broadly, these studies may offer insight into how 
the interaction between environmental exposures and pre-existing genetic 
alterations lead to disease. 
Chapter 2 examines basal-like associated copy number events and cell-line 
functional studies that focus on disrupting two prominent members of the BRCA1-
repair pathway in normal cell lines in order to imitate the basal-like tumor genetic 
environment, and generate a DNA damage sensitizing phenotype.  Chapter 3 
investigates a novel form of genomic instability that is associated with BBT and may 
be a hallmark of the defective mechanisms of DNA repair/genomic maintenance in 
this subtype.  Lastly, in Chapter 4, INPP4B, a gene that is frequently and specifically 
lost in BBT and a key member of the PI3K signaling pathway is evaluated as a 
contributing factor involved in BBT formation. 
There is currently a paucity of effective treatments for BBT, which is a 
leading cause of cancer deaths in women.  We must more precisely understand how 
the BRCA1 pathway is dysregulated in order to take advantage of these defects to 
design effective treatment regimens for BBT.  Greater understanding of the 
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molecular causes of BBT could be obtained by the eventual generation of mouse 
models with the same dysregulation events we are investigating.  Further 
characterization of the DNA repair functionality of BBT will increase our 
understanding of their response to chemotherapeutics, and could identify points of 
intervention for the prevention and improved treatment of BBT.   
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1.6  Figures and Legends 
 
Figure 1.1:  Normal, human mammary gland stained for identifying markers. 
 
Normal breast tissue stained for proteins that mark luminal epithelial cells (ER, 
GATA3, CK 8/18) or myoepithelial cells (SMA, CK17, CK5/6). 
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Figure 1.1 
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Figure 1.2:  Hierarchical clustering of human breast tumors. 
 
A combined dataset of 324 tumor samples collected at UNC and 329 tumors from 
the NKI, was clustered using the intrinsic gene set (Hu et al. 2006).  Clustering 
identified the six major intrinsic subtypes: luminal A, luminal B, normal breast-like, 
basal-like and HER2-enriched, and claudin-low.  
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Figure 1.2 
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Figure 1.3:  Kaplan-Meier plot depicting overall survival for each subtype. 
 
Kaplan-Meier analyses examining overall survival outcomes according to tumor 
subtype. 
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Figure 1.3: 
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Figure 1.4:  Genomic landscapes of each breast cancer subtype. 
 
Genomic copy number landscapes indicating the frequency of copy number gains 
and losses across the genome for A) Basal-like (N=40), B) LumA (N=52), C) LumB 
(N=40), D) Her2 (N=21), and E) Claudin-low (N=15). 
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Figure 1.4  
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Figure 1.5:  PARP inhibitor ABT-888 sensitivity in basal-like cell lines. 
 
IC50 doses (72h) of ABT-888 on a normal, basal-like cell line (HME-CC) versus that 
of two basal-like tumor cell lines (SUM149, SUM102).  Each MTT experiment was 
performed in triplicate and error bars represent 95% confidence intervals. 
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Figure 1.5 
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Figure 1.6:  Expression of genes in the BRCA1/DNA repair pathway in basal-
like breast cancer. 
 
Data is displayed using Cytoscape 2.61, a pathway modeling program.  Average gene 
expression for basal-like breast cancer is shown relative to the Luminal A subtype 
from a dataset of 250 tumors with known subtype, in which the average gene 
expression value for each gene was calculated for each subtype.   
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CHAPTER TWO 
BASAL-LIKE BREAST CANCER DNA COPY NUMBER LOSSES IDENTIFY GENES 
INVOLVED IN GENOMIC INSTABILITY, RESPONSE TO THERAPY, AND PATIENT 
SURVIVAL 
 
  
2.1  Introduction 
Breast cancer is a heterogeneous disease with known expression defined 
tumor subtypes.  DNA copy number studies have suggested that tumors within gene 
expression subtypes share similar DNA Copy Number Aberrations (CNA) and that 
CNA can be used to further sub-divide expression classes.  To gain further insights 
into the etiologies of the intrinsic subtypes, we classified tumors according to gene 
expression subtype and next identified subtype-associated CNA using a novel 
method called SWITCHdna, using a training set of 180 tumors and a validation set of 
359 tumors.  Fisher’s Exact tests, Chi-square approximations, and Wilcoxon rank-
sum tests were performed to evaluate differences in CNA by subtype. To assess the 
functional significance of loss of a specific chromosomal region, individual genes 
were knocked down by shRNA and drug sensitivity and DNA repair foci assays 
performed.  Most tumor subtypes exhibited specific CNA. The Basal-like subtype 
was the most distinct with common losses of the regions containing RB1, BRCA1, 
INPP4B, and the greatest overall genomic instability. One Basal-like subtype 
associated CNA was loss of 5q11-35, which contains at least three genes important 
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for BRCA1-dependent DNA repair (RAD17, RAD50, and RAP80); these genes were 
predominantly lost as a pair, or all three simultaneously. Loss of two or three of 
these genes was associated with significantly increased genomic instability and poor 
patient survival. RNAi knockdown of RAD17, or RAD17/RAD50, in immortalized 
human mammary epithelial cell lines caused increased sensitivity to a PARP 
inhibitor and carboplatin, and inhibited BRCA1 foci formation in response to DNA 
damage.  These data suggest a possible genetic cause for genomic instability in 
Basal-like breast cancers and a biological rationale for the use of DNA repair 
inhibitor related therapeutics in this breast cancer subtype. 
Previous gene expression profiling studies of human breast tumors have 
shaped our understanding that breast cancer is not one disease, but is in fact many 
biologically separate diseases. A classification of tumors by expression profiling into 
five distinct groups (Luminal A, Luminal B, HER2-enriched, Basal-like, and Claudin-
low subtypes) has added prognostic and predictive value to the existing repertoire 
of biomarkers for breast cancer (Prat et al. ; Perou et al. 2000; Sorlie et al. 2001; 
Sorlie et al. 2003; Hu et al. 2006; Parker et al. 2009).  For many cancers, improper 
maintenance of genome stability is a major cause of tumorigenesis and thus, the 
characterization of the tumor genomic DNA landscape is an important avenue of 
investigation (Pinkel and Albertson 2005).  Array comparative genome 
hybridization (aCGH) studies of tumor copy number states have demonstrated that 
tumors with similar gene expression subtypes may also share similar DNA Copy 
Number Aberrations (CNA) (Russnes et al. ; Bergamaschi et al. 2006; Chin et al. 
2006; Wood et al. 2007; Van Loo et al. 2010) and that CNA can be used to further 
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sub-divide expression classes (Russnes et al.).  In breast cancers, genomic 
instability-driven tumorigenesis is most prevalent in the Basal-like subtype (also 
referred to as Triple-Negative Breast Cancers), where the majority of tumors exhibit 
many CNA (Ding et al. ; Russnes et al. ; Bergamaschi et al. 2006; Chin et al. 2006; Van 
Loo et al. 2010). Identifying the genes that contribute to this instability phenotype 
would be useful not only from a biological perspective, but also possibly as a clinical 
predictor of therapeutic response. 
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2.2  Results and Discussion 
Identifying Subtype-Specific Regions of Copy Number Aberration 
To identify CNA that might be causative of Basal-like breast cancers, we 
assembled a dataset of 180 tumors with Agilent gene expression microarrays and 
Illumina 109,000 SNP marker DNA copy number microarrays (UNC-NW). We 
classified each tumor into one of five previously defined expression subtypes using 
the published intrinsic subtypes (i.e. PAM50) and Claudin-low subtype predictors 
(Prat et al. ; Parker et al. 2009). To identify regions of copy number gain/loss, we 
developed a new segmenting method called “SWITCHdna” (Sup Wald Identification 
of copy CHanges in dna).  Specifics of the SWITCHdna method can be found at 
https://genome.unc.edu/pubsup/SWITCHdna/.   
SWITCHdna identified regions/segments of copy number gains and losses in 
each tumor, which were then aggregated based on subtype to look at the frequency 
of each copy number event in each subtype and identify regions specific to each 
subtype (Figure 2.1 and Supplementary Table 2.1). A heatmap display of the copy 
number data is provided in Supplementary Figure 2.1. A number of new findings 
were observed including the first aCGH characterization of the Claudin-low subtype 
(Figure 2.1B). Despite its high grade and similarity to Basal-like tumors (Prat et al. ; 
Parker et al. 2009), Claudin-low tumors showed few copy number changes, which 
may correspond to the previously described ER-negative and copy number neutral 
tumor subtype reported in Chin et al (Chin et al. 2007). In addition, human Claudin-
low cell lines, which are often called “Basal B” lines, also have a similar flat copy 
number profile of showing very few chromosomal abnormalities (Kao et al. 2009). 
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We next searched for CNA occurring specifically within each subtype (Figure 
2.1A-F, black shading). The Basal-like subtype had the most subtype-specific events 
(Figure 2.1A, G) including the previously described amplicon at 10p containing 
MAP3K8, ZEB1, and FAM107B (Ding et al. ; Adelaide et al. 2007; Bergamaschi et al. 
2008), 16q loss (Haverty et al. 2008), deletion of 5q11-35 (Bergamaschi et al. 2006), 
and deletion of 4q. This last region contains INPP4B, which has recently been 
identified as a potential tumor suppressor involved in the inhibition of PI3K 
signaling (Gewinner et al. 2009) and that is selectively lost in Basal-like/Triple-
negative breast cancers (Fedele et al.). 
Basal-like tumors have previously been observed to have copy number loss 
and/or low expression of genes involved in BRCA1 DNA damage repair (Natrajan et 
al.), and we noted that loss of 5q11-5q35 would delete several genes involved in 
BRCA1-dependent DNA repair including RAD17, RAD50 (Johannsdottir et al. 2006), 
and RAP80 (Figure 2.1H).  Closer examination of the pattern of loss of these genes 
revealed that each gene was rarely lost as an individual event, but predominantly 
lost as a pair or triplet (Table 2.1A).  These doublet or triplet losses occurred at the 
highest rates in the Basal-like subtype, but also occurred less frequently in the 
HER2-enriched subtype.  These paired or triplet losses were not simply due to loss 
of the entire chromosomal arm as >65% of the analyzed tumors did not show a loss 
pattern indicative of such an event and several samples had intervening regions of 
normal copy number.  Loss of 5q11-35 was also found to statistically co-occur with 
CNA of other regions including 10p amplification (~50%), INPP4B/4q31.21 loss 
(~40%), PTEN/10q23.31 loss (~40%), BRCA1/17q21 loss (~50%), and most 
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frequently loss of RB1/13q14.2 (~80%) (Table 2.1E), which are genes/regions that 
have all been previously shown to be associated with Basal-like Breast Cancers. 
In order to validate these subtype-specific findings observed in the UNC+NW 
dataset, we classified the samples in Jonsson et al. (Jonsson et al.) according to 
PAM50 and Claudin-low subtype predictors and performed similar supervised 
analyses using their BAC-based DNA copy number data; very similar associations 
between CNA and subtypes were observed (Table 2.2).  Jonsson et al. identified 6 
unique tumor subtypes based upon CNA landscapes, which we determined were 
highly correlated with our expression defined intrinsic subtypes (p-value < 0.001, 
Table 2.3); importantly, there was high overlap between our Basal-like subtype and 
their Basal-Complex phenotype, both of which showed the frequent loss of 5q11-35 
and amplification of 10p. 
Increased Genomic Instability of Tumors Associated with Loss of Specific 
Regions/Genes 
To objectively assess “genomic instability”, we calculated a loss/normal/gain 
value for every gene using the SWITCHdna assigned copy number states, and 
calculated the levels of genomic instability by subtype using the average number of 
gains/losses per sample on a gene by gene basis. The Basal-like subtype was the 
most prone to aberrations, while the Claudin-low and Luminal A subtypes showed 
the lowest number of gene-based CNA (Table 2.1C).  To control for a large number 
of genes being gained or lost by a large single genomic aberration event (i.e. whole 
chromosome loss), we also calculated the average number of SWITCHdna-defined 
segments and their length for each subtype, as more genomic breaks will result in 
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more segments.  The subtypes that had greater numbers of gene aberrations were 
also the same ones that had more SWITCHdna segments of shorter average length 
(Table 2.1C).  Thus, the increased number of aberrant gene-based events in the copy 
number unstable subtypes was due to more frequent aberrations in the genome, 
rather than as a large number of genes gained or lost by a few large-in-size 
aberration events. 
Tumors with loss of PTEN/10q23.31, RB1/13q14.2, or TP53/17p13.1, or 
amplification of the 10p region were also found to have high rates of total gene-
based CNA compared to tumors without loss of these genes (Table 2.4).  Loss of 
5q11-35 was also associated with the highest numbers of CNA, with the greatest 
instability seen when all three DNA repair genes were lost. 
Low Expression of Genes Residing in Basal-like Regions Correlates with Poor Survival 
and Predicts Therapeutic Response 
To determine if these DNA loss events also impacted gene function, we 
determined whether the mRNA levels of candidate genes contained within these 
regions correlated with DNA loss. The expression of 10 genes selected based on 
their associations with the basal-like subtype, or breast cancer in general, was 
evaluated. Most of these genes showed significantly lower mRNA expression when 
the genomic DNA was lost including RAD17, RAD50, RAP80, MSH3, RB1, PTEN, 
BRCA1, and INPP4B (Figure 2.2); these data suggest that these losses have functional 
consequences (noting that only TP53 and BRCA2 did not show in cis correlation 
between expression and copy number). It is also of note that MSH3 (a gene involved 
in DNA mismatch repair), is located within the 5q11-35 loss region (between RAD17 
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and RAD50, Figure 2.1H), and it also showed reduced mRNA expression when lost 
and low expression within Basal-like tumors in general (Figure 2.2, 2.3E). In 
addition, the mRNA expression levels of RAD17, RAD50, MSH3, RAP80, INPP4B, and 
PTEN were lowest in the Basal-like subtype (Figure 2.3, UNC337 expression dataset 
(Prat et al.)); thus loss of 5q11-35 likely affects multiple aspects of DNA repair. 
Using patient survival data from two additional data sets containing gene 
expression data (UNC337 (Prat et al.) and NKI295 (van de Vijver et al. 2002)), 
Kaplan-Meier analysis showed that the low average expression of RAD17+RAD50 
was associated with worse outcomes compared to high expression (Figure 2.4A).  A 
similar trend was observed with INPP4B, mirroring previous observations (Figure 
2.4B) (Gewinner et al. 2009).  RAD17+RAD50 expression was also examined for 
treatment effects using the Hess et al. dataset, which examined T/FAC neoadjuvant 
chemotherapy responsiveness across 130 breast cancer patients (Hess et al. 2006). 
Low expression of RAD17+RAD50 was correlated with pathological complete 
response (pCR) (ANOVA p-value <0.0001). This finding may be due to the 
association between low expression of RAD17+RAD50 and Basal-like tumors, as 
Basal-like tumors have also been shown to have high neoadjuvant chemotherapy 
pCR rates (Rouzier et al. 2005; Carey et al. 2007). 
Knockdown of RAD17 +/- RAD50 Affects Sensitivity to Chemotherapeutics and BRCA1 
Foci Formation 
Given the involvement of RAD17, RAD50 and RAP80 in the BRCA1-DNA repair 
pathway, we determined whether disruption of these genes via RNAi knockdown 
would lead to changes in sensitivity to drugs whose mechanism of action has 
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already been linked to BRCA1 loss like carboplatin/cisplatin (Chang et al. ; Silver et 
al.) and PARP inhibitors (Huang et al. 2003; Donawho et al. 2007). RAD17 was 
stably knocked down with shRNA in the HME-CC cell line (an hTERT immortalized 
Human Mammary Epithelial Cell) (Troester et al. 2004) and knockdown was 
confirmed by Western blotting (Figure 2.5A). HME-CC cells with RAD17 knockdown 
exhibited increased sensitivity to ABT-888 (PARPi) and carboplatin (Figure 2.5C).  
No difference in paclitaxel sensitivity was observed, which was used as a non-DNA 
damaging agent control.  A RAD50 knockdown line did not exhibit any change in 
sensitivity to ABT-888 and had a paradoxical increase in resistance to carboplatin. 
We next emulated the most common in vivo co-occurring loss by generating a 
double knockdown of RAD17 and RAD50, which showed the greatest increased 
sensitivity to ABT-888 and carboplatin (Figure 2.5C).  Similar results were observed 
when this experiment was repeated in ME16C cells, a second hTERT-immortalized 
human mammary epithelial cell line (Supplementary Figure 2.2). 
In order to assess the effects of RAD17/RAD50 loss on BRCA1-dependent DNA 
repair, we performed a DNA repair foci formation assay on the control and 
RAD17+RAD50 double knockdown line. Using anti-BRCA1 protein 
immunofluorescence, and automated foci counting within geminin-positive cells, we 
observed a significant decrease in the number of BRCA1-containing DNA repair foci 
in the double knockdown line when treated with ionizing radiation or ABT888 
versus control (Figure 2.6); cells were simultaneously stained for geminin in order 
to control for differences in proliferation as described by Graeser et al. (Graeser et 
al. ; Gonzalez et al. 2004).  These data suggest that loss of RAD17 and/or RAD50 may 
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impair BRCA1 function, and could contribute to increased sensitivity to DNA 
damaging agents. 
Discussion 
The presence of distinct breast cancer expression subtypes suggests different 
underlying genetic events may be driving each subtype.  To address this hypothesis, 
we used 180 diverse tumors and performed supervised analyses of their tumor DNA 
copy number landscape and identified subtype-specific copy number events. Many 
studies have identified numerous regions of gain and loss in human breast tumors 
(Jonsson et al. ; Bergamaschi et al. 2006; Chin et al. 2006; Fridlyand et al. 2006; 
Haverty et al. 2008); however, most did not specifically search for regions uniquely 
associated with specific intrinsic subtypes.  Some previous attempts were made to 
identify basal-like specific CNA (Bergamaschi et al. 2006; Adelaide et al. 2007) and 
we observed a number of the same findings.  We take these previous findings as 
validation of our identified regions, and we build and expand upon these here, along 
with the addition of functional studies. 
Overall, we identified many subtype-specific CNA and validated these 
findings on a second, independent dataset. Here we have focused on the Basal-like 
subtype, which showed by far the greatest number of subtype specific CNA and 
were the most genomically unstable as determined by the sheer number of CNA, a 
feature which has been observed in the past (Chin et al. 2006). Basal-like tumors 
also showed consistent loss of 4q (which harbors INPP4B and FBXW7), and 5q11-35, 
which contains many DNA repair genes.  Basal-like tumors are known to be 
associated with BRCA1-pathway dysfunction in that 80-90% of BRCA1 mutation 
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carriers, if and when they develop breast cancer, develop Basal-like tumors (Foulkes 
et al. 2003; Sorlie et al. 2003; Arnes et al. 2005); however, in most sporadic Basal-
like tumors, the BRCA1 gene appears normal in sequence (Richardson et al. 2006). 
The loss of 5q11-35 may provide an alternative means to impair BRCA1-pathway 
function and explain why despite many Basal-like patients having normal BRCA1 
gene/protein, high levels of genomic instability and a “BRCAness” phenotype are 
observed in Basal-like tumors.  Previous evidence indicates a link between genes 
involved in BRCA1 DNA damage control and genes that are deleted and 
downregulated in Basal-like cancers, lending further credence to our hypothesis 
(Natrajan et al.). 
In order to expand our understanding of the relationship between the Basal-
like subtype and impaired BRCA1-pathway function, we pursued functional studies 
by RNAi mediated knockdown of two members of the pathway, RAD17 and RAD50, 
in order to emulate the genomic losses observed in tumors.  Besides being members 
of the BRCA1-pathway, others have highlighted these genes for their possible Basal-
like association, but without functional studies (Bergamaschi et al. 2006; 
Johannsdottir et al. 2006).  We show here that genetic ablation of these genes 
results in impaired DNA repair and increased drug sensitivity, and furthermore, 
deletion of RAD17 and RAD50 in yeast has also been shown to result in increased 
sensitivity to DNA-damaging agents including platinum drugs 
(http://fitdb.stanford.edu) (Hillenmeyer et al. 2008); these data highlight that there 
is an evolutionarily conserved role for these genes in DNA repair. 
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By building upon the discovery of the subtype association and the deletion 
phenotypes in yeast, we propose a role in DNA repair function for the 5q11-35 
region.  The drug sensitivity assays show the importance of these genes in DNA 
damage sensitivity and the foci formation experiments show that their function is 
mediated through BRCA1.  Additionally, from the combination of our genomic 
analyses and functional data, it is our hypothesis that the somatic loss of RAD17, 
RAD50 and/or RAP80 leads to impaired BRCA1-pathway function, impaired 
homologous recombination mediated DNA repair, and thus, contributes to overall 
genomic instability. 
There are, however, two caveats to these analyses and our hypothesis.  First, 
the 5q11-35 loss is a large region that typically involves >100 genes, therefore, we 
cannot definitively say that loss of these 3 genes is the target of this deletion, or that 
these 3 genes are the most important targeted genes of this region. Second, a high 
frequency of co-occurrence with other DNA chromosomal losses happens in tumors 
with 5q11-35 loss; for example, in ~80% of tumors with 5q11-35 loss, RB1/13q14.2 
DNA loss also occurs (and by itself is associated with increased genomic instability). 
In addition, ~60% of these tumors show TP53/17p13.1 loss (Table 2.1 and 2.2). The 
co-occurrence of 5q11-35 loss with RB1 and TP53 loss are likely causative events in 
Basal-like carcinogenesis (the latter two being corroborated by mouse studies) 
(Cressman et al. 1999; Herschkowitz et al. 2007; Jiang et al. 2010). Given the high 
co-occurrence of chromosome region losses that are not physically linked, it is 
impossible to say which one is the cause of the genomic instability. However, our 
hypothesis is that each of these regions harbors genes needed for maintenance of 
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the genome and that the combinatorial loss of 2-3 of these regions is what results in 
the genomic instability phenotype seen in Basal-like breast cancers. In this paper, 
we examine DNA losses, but do note that it is possible that loss of these same genes 
could also occur via methylation, altered microRNA regulation, and/or somatic 
mutation, although the latter has yet to be found when searching current somatic 
mutation databases for RAD17/RAD50/RAP80. Preliminary sequence analysis of 
RAD17 and RAD50 (data not shown), as well as evaluation of previous breast cancer 
sequencing efforts (Sjoblom et al. 2006) and the COSMIC database (Bamford et al. 
2004), revealed few, if any, somatic variants/mutations in these two genes, which is 
consistent with the finding that loss of any one gene is rarely seen; thus, if loss of 
two or more genes is the target of this CNA, then somatic mutation of any one gene 
would not impart a selective tumorigenic advantage. Therefore, these data suggest 
that the target of 5q11-35 loss is two or more genes in this region, with loss of 
RAD17 and RAD50 likely contributing to genomic instability. 
Conclusions 
The gene expression-defined intrinsic subtypes of breast cancer are mirrored 
by DNA copy number changes. The Basal-like subtype is the most distinct in the 
copy number landscape world, and these subtype associated CNA have clinical 
implications. If 5q11-35 loss results in impaired homologous recombination 
mediated DNA repair, as was suggested by our in vitro studies and in vivo correlates, 
then the loss of this region may sensitize tumors to specific classes of DNA damaging 
agents. Based upon BRCA1 studies in vitro (Quinn et al. 2003; Farmer et al. 2005) 
and in vivo (Silver et al. ; Donawho et al. 2007), these drugs could include PARP 
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inhibitors and cis/carboplatin. Loss of RAD17+RAD50 (mRNA and/or genomic DNA) 
may thus be a biomarker of chemotherapy responsiveness, which is supported by 
our finding of an association for predicting a likelihood of achieving a pathological 
complete response. We hypothesize that the loss of these DNA repair genes and the 
5q11-35 region, contributes to genomic instability and mutability, ultimately 
causing high proliferation rates and aggressive behaviors. Our integrated studies of 
gene expression and genomic DNA copy number have identified important 
pathway-based determinants of Basal-like cancers and a possible therapeutic 
biomarker.  
 
All relevant gene expression and copy number data new to this manuscript 
can be found in the GEO database under series GSE10893. 
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2.3  Materials and Methods 
Breast Cancer Patient Datasets 
Three patient datasets were used in this study, each of which contained gene 
expression and DNA copy number microarray data. We combined 2 sets into a single 
training set (n=180 with expression and copy number) so that we could have 
increased statistical power to detect subtype-specific CNA. The combined training 
set included one set of breast tumors from the United States (“UNC”) (n=77) and 
another set of tumors from Norway (“NW”) (n=103). The third data set (“Jonsson”) 
was used as a validation/testing set (n=359)(Jonsson et al.).  All samples were 
collected using IRB-approved protocols and all patients signed informed consent 
forms. Tumors in the training set were assayed for gene expression patterns using 
Agilent DNA microarrays. In total, the UNC gene expression cohort contained 337 
human breast tumors (UNC337), taken from Prat et al. 2010 (Prat et al.). Log2 ratio 
data was taken from the UNC Microarray Database (UMD), filtering for a lowess 
normalized intensity value of 10 or above for each channel, and 70% good data, and 
then used for further analyses.  Data is available from Gene Expression Omnibus 
under series GSE10893 
(http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?token=tdodziqaacgembc&acc=GS
E10893).  Sample information including clinical data, subtype, source, GEO Sample 
ID and overlap with copy number information, can be found in the UMD 
(https://genome.unc.edu) under published data (Weigman et al.). A subset of this 
UNC expression data set (n=77) was assayed for copy number changes using 
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Infinium Human-1 109K BeadChip (Illumina, San Diego, CA, USA) and results are 
described here. 
The Norway (NW) data set consists of 103 previously published breast 
tumors assayed on custom Agilent Microarrays for gene expression (GSE3985), and 
for copy number changes also using Infinium Human-1 109K BeadChip (Naume et 
al. 2007; Nordgard et al. 2008) (also listed under GEO GSE10893). The Jonsson 
dataset consists of 359 breast tumors assayed using custom produced 
oligonucleotide microarrays for gene expression, BAC microarrays for copy number, 
and which has been previously published (Jonsson et al.) in GEO series GSE22133. 
Clinical and gene expression data was also used from an additional dataset, the 
Netherlands Cancer Institute breast cancer dataset (NKI-295, n=295) (van de Vijver 
et al. 2002).  
Classifying tumors for expression-based subtype classification 
 The Lowess normalized R/G Log2 ratio data from the UNC337, NW103 and 
Jonsson-359, were used and median centered independently within each data set, 
prior to collapsing (via averaging) from probes to HGNC gene symbols.  Datasets 
were then limited to the gene symbols shared across them.  After column 
standardization of both datasets (samples at N(0,1)), Distance Weighted 
Discrimination (DWD) (Benito et al. 2004) was used  to remove platform bias and 
combine the UNC and NW datasets prior to classification.  The  PAM50 gene set 
predictor(Parker et al. 2009) in conjunction with a newly identified Claudin-low 
predictor(Prat et al.) was used to assign subtypes to the tumors in these three 
datasets.  
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Assessment of tumor genomic DNA copy number changes 
77 UNC and 103 NW samples had blood/normal and tumor DNA pairs each 
assayed using the Infinium Human-1 109K BeadChip (Illumina, San Diego, CA, USA), 
with an average resolution of 1 probe per 26kb (median of 1 probe per 13kb).  
Tumor content for each sample was assessed by histology to be greater than 50% 
tumor tissue.  Additionally, tumor cellularity was also assessed genomically by the 
ASCAT (Van Loo et al. 2010) and genoCNA (Sun et al. 2009) algorithms.  Each 
sample was labeled, hybridized, scanned and analyzed according to the 
manufacturer’s protocol (Gunderson et al. 2005). To account for germline specific 
copy number polymorphisms, a pool of 118 blood-drawn DNA samples was 
compiled and used as Illumina’s standard clustering reference through the 
BeadStudio software, which estimates allele-specific intensity boundaries.  
Genotype reports and LogR values were extracted with reference to dbSNP's (build 
125) forward allele orientation using BeadStudio (v3.1, Illumina, San Diego, CA, 
USA).  Sample information is in Additional Data File 1 and LogR (A+B signal) values 
can be found on GEO under series GSE10893, platform GPL8139. 
Identification of CNA with SWITCHdna 
 To determine regions of copy number aberration (CNA), we developed a new 
analysis method that is a modification of the SupWald method (Andrews 1993; Bai 
1998), where we created an R suite of functions called “SWITCHdna”, to identify 
breakpoints in aCGH data.  Statistical problems in aCGH analysis are the detection of 
transition points (positions where DNA copy numbers change) along with 
identifying most-likely false positive candidates. In SWITCHdna, the estimation of 
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number of transition points (K) is performed sequentially. First, we test for the 
presence of at least one transition point (versus none) across the entire 
chromosome. If the test shows no significant deviation from the null model (or no 
change points) we accept K=0. Otherwise, we find the change point that maximizes 
the F statistic and continue and test for the presence of the two change points 
(versus one) and so on.  We accepted a change point when the minimum of two 
criteria were met: 1) size of region on either side of the breakpoint was larger than 
 (number of observations (in our case, array probes) which would cover user-
defined range) and 2) the F statistic of each segment was the maximum value 
possible and above the user-specified threshold.  Following detection of the 
transition points, a segment average value and corresponding z-score, are 
determined along with the number of observations used.   
A significance filter was applied to the raw SWITCHdna-identified segments 
in order to reduce noise and increase the probability of identifying biologically 
relevant regions.  To determine this significance cutoff, we created 100 permuted 
datasets from our LogR ratio values, which had values shuffled within the space of 
each chromosome.  SWITCHdna was then run on each of these permuted datasets to 
gather information about random segment statistics.  We found that a z-score of 3 or 
greater, and intensity cutoff of 0.1 was sufficient to select for values with a 
familywise error rate of 5% (data not shown).   All subsequent plots and tables were 
produced after applying this significance filter to our data.  Plotting functions 
(plot.freq.SW) display the prevalence of subtype-shared CNA in genome-space.  
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SWITCHdna is provided as a source script in R(R Development Core Team 2009) 
and  available for download at: https://genome.unc.edu/pubsup/SWITCHdna/. 
Determining subtype-specific CNA 
 Using the cnaGENE function of SWITCHdna, the segment output file was 
converted into an indicator matrix, where for each sample, each gene’s copy state 
was represented as -1 = loss, 0 = no change, 1 = gain.  This happens first on a 
segment basis, with individual gene data then being taken from the segment value; 
specifically SWITCHdna first identifies the gain/loss segments of a sample, the 
cnaGENE function filters segments by providing thresholds for Z score and Intensity 
levels (that can be determined through permuting probe loci and rerunning 
SWITCH).  When a segment passes filtering, all genes that fall completely within that 
segment are assigned a gain/loss status as appropriate to the sign of the segment. 
For genes that may be split by a segment, we assigned a value of unchanged=0, 
because it was split and thus, giving 2 possible values; the split genes were a 
minority of the genes and this only affected <0.5% of genes across all samples. For 
each subtype, the counts of gains and losses were compared versus all other 
samples in order to identify subtype-specific CNA.  A Fisher’s Exact test was 
performed on the subtype vs. rest counts for each gene.  The resulting p-values were 
adjusted by the Benjamini-Hochberg method (Benjamini and Hochberg 1995) to 
correct for multiple-hypothesis testing and then genes with p-values < 0.05 were 
then gathered for each subtype.  Regions within the cytobands of localized CNA 
were determined by the significant genes found within each cytoband, allowing for 
more separation of CNA loci (Supplementary Table 2.1).   
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RNAi Cell Line experiments 
Stable RNAi knockdown lines were generated from hTERT-immortalized, 
human mammary epithelial cell lines (HME-CC and ME16C) cultured as described in 
Troester et al (Troester et al. 2006).  Genes were targeted with shRNA constructs for 
RAD17 (Oligoengine) and RAD50 (Origene) (RAD17 – UGCCAUACCUUGCUCUACU, 
GUGGAAAGACAACGACCUU; RAD50: TI308519 – 
CTTCAGACAGGATTCTTGAACTGGACCAG, CTCAACTGTGGCATCATTGCCTTGGATGA) 
and control lines were concurrently made using a non effective construct (Origene – 
TR30003, Oligoengine – VEC-PRT-0006). 10g of each vector was transfected into 
Phoenix 293T cells using Lipofectamine 2000 (Invitrogen) as per manufacturer’s 
instructions to produce retrovirus. Viral supernatant was collected and applied to 
the cell line with 75ug of polybrene.  Stable populations were selected by culturing 
in 400mg/mL geneticin for the RAD17 knockdown line and its control and 1mg/mL 
puromycin for the RAD50 knockdown line and control. 
Western Blot Analysis 
Cells were grown in 10-cm tissue culture-treated dishes to 80% confluence 
and then harvested, protein isolated, and quantified as described previously 
(Troester et al. 2004).  Membranes were probed for RAD17 (AB3261; Millipore, 
Billerica, MA, USA), RAD50 (#3427; Cell Signaling Technology, Danvers, MA, USA), 
alpha-tubulin (sc-9104, Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA), or actin 
(GTX 21801, GeneTex, Irving, CA, USA) followed by anti-rabbit or anti-goat IgG 
horseradish peroxidase-linked whole antibody (sc-2020; Santa Cruz Biotechnology, 
Inc., Santa Cruz, CA, USA or Amersham Biosciences, Piscataway, NJ USA) and 
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detected using SuperSignal West Pico Chemiluminescent Substrate (Pierce, 
Rockford, IL, USA). 
Cell Cytotoxicity Assays 
 Sensitivity to drugs was assessed by a modified mitochondrial dye-
conversion assay (Cell Titer 96, Promega #G4100, Madison, WI, USA) as described 
(Troester et al. 2004; Hoadley et al. 2007).  Carboplatin and paclitaxel were 
purchased from UNC Hospital Pharmacy (Chapel Hill, NC, USA).  ABT-888 was 
generously provided by the Center for Integrative Chemical Biology and Drug 
Discovery (CICBDD) and the University Cancer Research Fund at the University of 
North Carolina. 72h inhibitory concentrations that caused a 50% reduction in MTT 
(3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide) dye conversion 
(IC50) were determined using nonlinear regression (Van Ewijk and Hoekstra 1993). 
BRCA1 Foci Formation Assay 
 HME-CC cells were seeded into 4-chamber well slides at an initial 
concentration of 50,000 cells per well, allowed to adhere, then irradiated with 2.5 
Gy of ionizing radiation with 20 minute recovery, or treated with 200 M ABT-888 
for 24h, or left untreated.  After treatment, cells were fixed with 4% 
paraformaldehyde, permeabilized with 0.2% Triton X-100 solution, then 
immunostained with primary antibody (BRCA1, Santa Cruz, sc-6954) and Alexa-488 
(Invitrogen) conjugated secondary antibody and counterstained with DAPI.  Cells 
were also stained with geminin antibody (GMNN, ProteinTech, 10802-1-AP) and 
Alexa-568 (Invitrogen) conjugated secondary antibody.  Images were taken with 
Leica SP2 confocal microscope with a 63X objective lens.  Foci counts were 
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performed using a MetaMorph 7.0 (Molecular Devices) analysis module with foci 
being scored as areas of 2-5 pixel width with 70 gray levels above local background 
intensity. At least 5 fields of view were scored, per sample, per treatment category. 
Survival Analysis 
 A mean expression value for RAD17+RAD50, and INPP4B, for each patient 
tumor in the UNC337 and NKI295 (van de Vijver et al. 2002) datasets was 
determined and patients were rank-ordered and separated into three equal groups 
representing low, medium, and high average expression for each gene or combined 
genes. Survival analyses were performed using the Kaplan-Meier test in R. 
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2.5  Figures and Legends 
 
Figure 2.1:  Copy number frequency plots from SWITCHdna show regions of 
aberrations shared by members of the same subtype. 
 
Grey shading indicates regions of change with the y-axis representing frequency of 
aberration at each site within each subtype.  Regions in black were statistically 
associated with a particular subtype and remained significant after Benjamini-
Hochberg correction. Regions below the center (negative values) represent losses, 
and areas above the center (positive values) indicate gains.  A) Basal-like, B) 
Claudin-low, C) HER2-enriched, D) Luminal A, E) Luminal B, and F) Normal-like.   G) 
Expanded view of the Basal-like copy number landscape.  INPP4B, MAP3K8, 
FAM107B, and ZEB1, each in Basal-like specific regions of CNA, are marked.  BRCA1, 
BRCA2, PTEN, RB1, and TP53, are genes/regions that were frequently, but not 
specifically, lost in the Basal-like subtype, and KRAS, which is frequently but not 
specifically gained in the Basal-like subtype, are also noted.  The dotted horizontal 
lines indicate 50% gain or loss.  H) Enlarged view of the Basal-like chromosome 5q 
region showing the location of RAD17, MSH3, RAD50, and RAP80.  Loss frequency is 
indicated on the y-axis and the level of 50% loss is highlighted by the dotted line. 
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Figure 2.1 
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Figure 2.2:  Numerous genes in the UNC-Norway dataset have low gene 
expression associated with DNA copy number loss.   
 
Gene Expression values for RAD17, RAD50, RAP80, MSH3, BRCA1, BRCA2, PTEN, RB1, 
TP53, and INPP4B in the UNC-Norway dataset (n=180) separated by copy number 
status (DNA copy number loss vs. no loss).  p-values determined by ANOVA test. 
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Figure 2.2 
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Figure 2.3:  ANOVA boxplots for individual genes that are commonly lost in 
Basal-like cancers according to intrinsic subtype determined using the 
UNC337 sample set. 
 
p-values were determined by 2-way ANOVA.  A) RAD17, B) RAD50, C) RAP80, D) 
PTEN, E) MSH3, and F) INPP4B. 
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Figure 2.3 
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Figure 2.4:  Survival analysis according to expression of RAD17+RAD50 and 
INPP4B. 
 
Patients in the UNC337 and NKI295 datasets were rank-ordered organized by 
average gene expression values of A) RAD17+RAD50 combined, or B) INPP4B.  The 
patients were split into 3rds based upon rank-order expression values and Kaplan 
Meier analysis was done on the three groups to examine trends in relapse-free 
survival and overall survival.  p-values determined by log-rank test. 
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Figure 2.4 
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Figure 2.5:  RNAi knockdown experiments in an immortalized HMEC (BABE 
cell line).   
 
Western blot analysis showing reduction of RAD17 and RAD50 protein expression 
in HME-CC A) single, or B) double RNAi knockdown lines.  (KD, knockdown line; C, 
vector control line).  Tubulin staining was performed as a loading control.  C) 
Estimated IC50 with 95% CI for ABT-888, Carboplatin, and Paclitaxel based on 
mitochondrial dye-conversion assay.  Results are based on the average of two 
experiments per condition, each done in triplicate, with knockdown-control pairs 
with significant differences in IC50 are designated with a *. 
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Figure 2.5 
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 Figure 2.6:  BRCA1-mediated DNA repair foci formation assay.   
 
A) Representative images of BRCA1 foci formation in RAD17-RAD50 Double 
Knockdown cells and control cells after treatment with 2.5 Gy of ionizing irradiation 
and 20 minute recovery (Ionizing Radiation), or no treatment (Untreated).  B) 
Representative images of BRCA1 foci formation in RAD17-RAD50 Double 
Knockdown cells and control cells with 200 M ABT-888 (ABT-888), or no 
treatment (Untreated).  Green channel - BRCA1, Red channel – Geminin, Blue 
Channel - DAPI images.  All images were taken with a 63x objective and post 
processed to 300% of its original size.  Automated BRCA1 foci counting results from 
each cell line for C) ionizing radiation and D) ABT-888 treatment.  Error bars 
represent 95% confidence intervals (* p<.05 of knockdown relative to control).  p-
values were calculated from t-tests comparing foci counts in treated Double 
Knockdown cells versus treated Control cells or untreated Double Knockdown cells 
versus untreated Control cells. 
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Figure 2.6 
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Table 2.1:  Frequency of copy number alterations data for the UNC-Norway 
combined dataset.   
 
Data is shown for selected A) deletions, B) amplifications, C) average number of 
changes, D) % Tumor Cellularity, and E) co-occurrences.  Values are presented in 
‘Count (%)’ format.  Specific counts are given for individual deletions or co-
deletions, with each sample only classified into one category. C) Counts for average 
gains/losses for each subtype. Total number of aberrations is the sum of all 
individual gene gains and losses. Average segment number and length were 
calculated from the SWITCHdna generated segments for each sample within each 
subtype.  D) % Tumor Cellularity generated by ASCAT algorithm or genoCNA 
algorithm.  E) Rates of co-occurrence of 5q cluster loss with other gene alterations 
are shown (N refers to the number of total samples with 5q loss).  Fisher’s Exact 
tests or Chi-square approximations were done to determine if the rates of 
occurrence, or co-occurrence, were at statistically significant levels. 
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Table 2.1 
 
 
 65 
Table 2.2:  Frequency of copy number alterations data for the Jonsson dataset. 
 
Data is shown for selected A) deletions, B) amplifications, C) average number of 
changes, and D) co-occurrences.  Values are presented in ‘Count (%)’ format.  
Specific counts are given for individual deletions or co-deletions, with each sample 
only classified into one category. C) Counts for average gains/losses for each 
subtype. Total number of aberrations is the sum of all individual gene gains and 
losses. Average segment number and length were calculated from the SWITCHdna 
generated segments for each sample within each subtype.    D) Rates of co-
occurrence of 5q cluster loss with other gene alterations are shown (N refers to the 
number of total samples with 5q loss).  Fisher’s Exact tests or Chi-square 
approximations were done to determine if the rates of occurrence, or co-occurrence, 
were at statistically significant levels. 
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Table 2.2 
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Table 2.3:  Comparison of Jonsson et al. copy number based classifications 
versus intrinsic subtypes. 
 
Subtype classifications using both the original labels in the Jonsson dataset (Jonsson 
et al.) using copy number defined subtypes, versus PAM50 plus Claudin-low gene 
expression subtypes is shown.  p-value determined by Chi-square approximation. 
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Table 2.3 
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Table 2.4:  Examination of possible correlations between the specific CNA and 
overall genomic instability.   
 
The average numbers of CNA for gains, losses, or both, are shown for the entire 
dataset and within sets of tumors with a given copy number alteration (5q, 
PTEN/10q23.31, RB1/13q14.2, TP53/17p13.1 and 10p).  A Wilcoxon-rank sum test 
was performed to see if the rate of copy number aberration between each group 
(Pairwise:  Aberration vs. Other, or No Aberration) was significantly different (*). 
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Table 2.4 
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Supplementary Figure 2.1:  Heatmap of copy number aberration landscape of 
the UNC-NW tumor training sample set. 
 
Samples were ordered by sample name within subtype and the data is presented in 
chromosomal order.  Red indicates increased copy number, black unchanged 
relative to normal, and green indicates decreased copy number. 
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Supplementary Figure 2.1 
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Supplementary Figure 2.2:  RNAi knockdown experiments in a second 
immortalized HMEC (ME16C). 
 
Western blot analysis showing reduction of RAD17 and RAD50 protein expression 
in A) single or B) double RNAi knockdown lines.  (KD, knockdown line; C, vector 
control line).  Actin staining was performed as a loading control.  C) Estimated IC50 
with 95% CI for ABT-888, Carboplatin, and Paclitaxel based on mitochondrial dye-
conversion assay.  Results for each condition are based on the average of an 
experiment done in triplicate, and knockdown-control pairs with significant 
differences in IC50 are designated with a *. 
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Supplementary Figure 2.2 
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Supplementary Table 2.1: List of the subtype-specific regions of aberration 
after multiple hypothesis correction, organized by subtype. 
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Supplementary Table 2.1 
 
Chromosome Start 
Position 
Stop 
Position 
Cytoband Gain/Loss 
Basal     
1 41717036 43943775 1p34.2 GAIN 
1 43945805 44960161 1p34.1 GAIN 
1 46541957 46555032 1p33 GAIN 
4 1234177 1683843 4p16.3 LOSS 
4 3220565 5553626 4p16.2 LOSS 
4 5577784 10295484 4p16.1 LOSS 
4 10979549 15266111 4p15.33 LOSS 
4 15313739 17632477 4p15.32 LOSS 
4 19864333 22430289 4p15.31 LOSS 
4 23402742 26636101 4p15.2 LOSS 
4 30331135 30753569 4p15.1 LOSS 
4 37121738 38804810 4p14 LOSS 
4 41057559 42353879 4p13 LOSS 
4 69085500 69570979 4q13.2 LOSS 
4 71492582 75938920 4q13.3 LOSS 
4 76623381 79684447 4q21.1 LOSS 
4 79691766 80079606 4q21.21 LOSS 
4 114219937 114355024 4q26 LOSS 
4 143168636 143603331 4q31.21 LOSS 
4 151218876 154929678 4q31.3 LOSS 
4 155375138 160500747 4q32.1 LOSS 
4 162524501 164492534 4q32.2 LOSS 
4 164612456 170167997 4q32.3 LOSS 
4 170251982 170915637 4q33 LOSS 
4 174326479 176135905 4q34.1 LOSS 
4 176791083 177486490 4q34.2 LOSS 
5 49730236 50173926 5q11.1 LOSS 
5 52119531 58183162 5q11.2 LOSS 
5 58300629 62108926 5q12.1 LOSS 
5 63292034 63701397 5q12.2 LOSS 
5 63838208 66501179 5q12.3 LOSS 
5 66513872 67633403 5q13.1 LOSS 
5 68425638 72913540 5q13.2 LOSS 
5 73958991 76396789 5q13.3 LOSS 
5 76408288 81082828 5q14.1 LOSS 
5 81303630 82685333 5q14.2 LOSS 
5 82803339 90714877 5q14.3 LOSS 
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Chromosome Start 
Position 
Stop 
Position 
Cytoband Gain/Loss 
5 92250850 96544700 5q15 LOSS 
5 98132900 102642260 5q21.1 LOSS 
5 102912456 102926389 5q21.2 LOSS 
5 106744250 109231328 5q21.3 LOSS 
5 109877429 111137815 5q22.1 LOSS 
5 111507433 112958878 5q22.2 LOSS 
5 113725565 115180304 5q22.3 LOSS 
5 115193714 121517156 5q23.1 LOSS 
5 121675719 127022221 5q23.2 LOSS 
5 127447382 129549383 5q23.3 LOSS 
5 130522776 135427403 5q31.1 LOSS 
5 135493104 138988200 5q31.2 LOSS 
5 139008130 142795270 5q31.3 LOSS 
5 143171919 147191453 5q32 LOSS 
5 147238467 151765017 5q33.1 LOSS 
5 152850499 154326721 5q33.2 LOSS 
5 155686345 159845035 5q33.3 LOSS 
5 159922707 167623739 5q34 LOSS 
5 167651670 171366482 5q35.1 LOSS 
5 172591744 174888201 5q35.2 LOSS 
5 176660805 180009206 5q35.3 LOSS 
6 13729714 14088212 6p23 GAIN 
6 42772314 43039595 6p21.1 GAIN 
9 831690 1047552 9p24.3 GAIN 
9 12683435 13935586 9p23 GAIN 
9 14071847 14900353 9p22.3 GAIN 
9 122980237 124410900 9q33.2 LOSS 
10 170643 1769670 10p15.3 GAIN 
10 3099740 3205003 10p15.2 GAIN 
10 3811260 6662244 10p15.1 GAIN 
10 7244255 12332593 10p14 GAIN 
10 12431738 17283687 10p13 GAIN 
10 17311250 19896508 10p12.33 GAIN 
10 20145174 20609292 10p12.32 GAIN 
10 21110098 22746531 10p12.31 GAIN 
10 22863772 24876778 10p12.2 GAIN 
10 24604620 28074753 10p12.1 GAIN 
10 28141103 31360860 10p11.23 GAIN 
10 31648148 32903498 10p11.22 GAIN 
12 42034279 44588086 12q12 LOSS 
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Chromosome Start 
Position 
Stop 
Position 
Cytoband Gain/Loss 
12 44599181 47397048 12q13.11 LOSS 
12 47446248 48387464 12q13.12 LOSS 
12 48421630 53099317 12q13.13 LOSS 
12 53136012 55168448 12q13.2 LOSS 
12 55201993 55269875 12q13.3 LOSS 
12 56621627 57600529 12q14.1 LOSS 
13 104916365 104941384 13q33.2 GAIN 
13 106620319 107317084 13q33.3 GAIN 
13 109973420 114110898 13q34 GAIN 
14 21961377 23608756 14q11.2 LOSS 
14 23609961 31698685 14q12 LOSS 
14 31868274 34078694 14q13.1 LOSS 
14 34100051 35410919 14q13.2 LOSS 
14 35837522 37090214 14q13.3 LOSS 
14 37128947 38971371 14q21.1 LOSS 
14 49113809 52311409 14q22.1 LOSS 
14 52311662 54325595 14q22.2 LOSS 
14 54378476 55837783 14q22.3 LOSS 
14 57736586 58085299 14q23.1 LOSS 
14 69312342 69568836 14q24.2 LOSS 
14 92049878 92765306 14q32.12 LOSS 
14 92773649 95250286 14q32.13 LOSS 
14 95740950 100105884 14q32.2 LOSS 
15 28193434 29022600 15q13.2 LOSS 
15 29020705 31945591 15q13.3 LOSS 
15 31945721 37862331 15q14 LOSS 
15 37880223 38115089 15q15.1 LOSS 
15 49136093 51017946 15q21.2 LOSS 
15 51593230 55368004 15q21.3 LOSS 
15 56490060 57176541 15q22.1 LOSS 
15 57184612 61461128 15q22.2 LOSS 
15 61583863 61913200 15q22.31 LOSS 
15 65899096 66370691 15q23 LOSS 
15 75011134 75564998 15q24.3 LOSS 
19 39664720 39962225 19q13.11 GAIN 
22 37740208 38258806 22q13.1 GAIN 
     
Her2     
2 159800558 163403274 2q24.2 GAIN 
2 164158152 168812365 2q24.3 GAIN 
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Chromosome Start 
Position 
Stop 
Position 
Cytoband Gain/Loss 
Luminal A     
16 45393460 45522699 16q11.2 LOSS 
16 45546775 51138307 16q12.1 LOSS 
16 51646446 54466783 16q12.2 LOSS 
16 54782803 56638303 16q13 LOSS 
16 56705000 65205296 16q21 LOSS 
16 65206155 69392572 16q22.1 LOSS 
16 69398793 73198518 16q22.3 LOSS 
16 73739922 78192112 16q23.1 LOSS 
16 79132355 80549399 16q23.2 LOSS 
16 80588753 82633263 16q23.3 LOSS 
16 82644872 85172804 16q24.1 LOSS 
16 85920445 87225756 16q24.2 LOSS 
16 87232502 87749670 16q24.3 LOSS 
     
Luminal B     
5 58300629 59320301 5q12.1 GAIN 
5 68425638 71536822 5q13.2 GAIN 
5 101597589 102642260 5q21.1 GAIN 
5 102912456 102926389 5q21.2 GAIN 
5 125787000 126200608 5q23.2 GAIN 
5 128458341 128477620 5q23.3 GAIN 
6 116369389 117096650 6q22.1 LOSS 
6 117109043 117359993 6q22.2 LOSS 
10 118946990 119027085 10q25.3 LOSS 
10 119032598 121691235 10q26.11 LOSS 
10 122206456 122883255 10q26.12 LOSS 
10 123223889 124739898 10q26.13 LOSS 
11 49383103 49393881 11p11.12 LOSS 
11 76710709 85146692 11q14.1 LOSS 
11 85633463 87710586 11q14.2 LOSS 
11 87881006 92269284 11q14.3 LOSS 
11 92342437 95765250 11q21 LOSS 
11 104262627 109547776 11q22.3 LOSS 
11 110631916 112776199 11q23.1 LOSS 
11 112785528 114880322 11q23.2 LOSS 
11 116803699 119605859 11q23.3 LOSS 
13 27611014 27767472 13q12.2 LOSS 
13 27774389 30804409 13q12.3 LOSS 
13 31211674 31275009 13q13.1 LOSS 
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Chromosome Start 
Position 
Stop 
Position 
Cytoband Gain/Loss 
20 40134806 41603948 20q13.11 GAIN 
20 41621022 45719023 20q13.12 GAIN 
20 45719063 49181611 20q13.13 GAIN 
20 49438571 52269898 20q13.2 GAIN 
20 61689399 61755226 20q13.33 GAIN 
 
 
 
 
  
CHAPTER THREE 
MICRO-SCALE GENOMIC COPY NUMBER ABERRATIONS AS ANOTHER MEANS OF 
MUTAGENESIS IN BREAST CANCER 
 
 
3.1  Introduction 
 In breast cancers, the Basal-like subtype has high levels of genomic 
instability relative to other breast cancer subtypes with many basal-like-specific 
regions of aberration. There is evidence that this genomic instability extends to 
smaller scale genomic aberrations as well, as shown by a previously described 
micro-event in the PTEN gene in the Basal-like SUM149 breast cancer cell line.  We 
sought to identify if small regions of genomic change exist, by using a high density, 
gene centric comparative genomic hybridization (CGH) array on both cell lines and 
primary tumors. A custom Agilent tiling array for CGH (244,000 probes, 200bp tiling 
resolution) was created to identify small regions of genomic change and was 
focused on previously identified basal-like specific, and general, cancer genes. 
Tumor genomic DNA from 94 patients and 2 breast cancer cell lines was labeled and 
hybridized to these arrays. Aberrations were called using SWITCHdna and the 
smallest 25% of SWITCHdna-defined genomic segments being called micro-
aberrations (<64 contiguous probes, ~ <15kb).  Our data showed that primary 
tumor breast cancer genomes frequently contained areas of small-scale copy 
number gains and losses, termed micro-aberrations, which are undetectable using 
lower-density genome-wide platforms. The basal-like subtype exhibited the highest 
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incidence of these events. These micro-aberrations sometimes altered expression of 
the involved gene as suggested by data from microarray and mRNA-seq studies. We 
confirmed the presence of the PTEN micro-amplification in SUM149 and by mRNA-
seq showed that this resulted in loss of expression of all exons downstream of this 
event. Micro-aberrations disproportionately affected the 5’ regions of the affected 
genes, including the promoter region, and a high frequency of micro-aberrations 
was associated with poor survival outcomes.  Using a high probe density, gene-
centric aCGH microarray, we present evidence of small-scale genomic aberrations 
that contribute to gene inactivation, and thus, genomic instability and tumor 
formation through a mechanism not detected using conventional copy number 
analyses. 
 A hallmark of many human cancers is genomic instability, and cancer itself 
can be thought of as the result of altered ploidy (Shen). The importance of studying 
the cancer genome cannot be understated as genomic alterations have been linked 
to cancer causation both broadly and in specific subgroups of patients (Rowley 
1973; Seshadri et al. 1989; Seshadri et al. 1993; Sakakura et al. 1999; Pinkel and 
Albertson 2005).  Alterations on a genomic level are likely to cause associated 
changes in gene expression (Tran et al. ; Jarvinen et al. 2008). Previous global gene 
expression profiling studies of breast carcinoma samples have identified at least five 
distinct subtypes of breast cancer (Perou et al. 1999; Perou et al. 2000; Sorlie et al. 
2001; Sorlie et al. 2003; Hu et al. 2006) and specific patterns of copy number 
aberrations (CNA) can also define genetic events associated with different subtypes 
(Weigman et al. ; Bergamaschi et al. 2006).  Continued investigation of copy number 
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abnormalities in breast cancer is likely to yield insights into the pathogenesis of the 
disease.   
 With the continued advancement in technology for copy number analysis and 
high-throughput microarray studies and next-generation sequencing, previously 
difficult to detect varieties of genetic abnormalities are beginning to be unraveled.  
Through the use of a high-density array comparative genomic hybridization (HD-
aCGH) platform, it is possible to detect both gross and fine-scale aberrations in 
genes (Xing et al. ; Saal et al. 2008).  Small-scale CNA, here termed micro-
aberrations, represent a previously under-investigated source of copy number 
variation that may shed light on breast subtype characteristics and tumorigenesis.  
Enhanced detection, cataloguing, and validation of these events could be an avenue 
through which we can gain a greater understanding of breast cancer genomes 
through the improved ability to detect genetic events affecting gene expression and 
function. 
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3.2  Results and Discussion 
Copy Number Micro-aberrations are Present in Breast Tumor Subtypes 
  In order to test the hypothesis that primary breast cancer genomes contain 
areas of small-scale copy number gains and losses, termed micro-aberrations, in 
addition to large-scale amplifications and deletions, we designed a custom, high-
resolution, high-density, comparative genomic hybridization tiling array (HD-aCGH) 
with an average probe resolution of 200 base pairs.  We assembled a dataset of 94 
tumors and 2 cell lines and tested them on this HD-aCGH array.  Each tumor was 
classified into one of five previously defined expression subtypes using the 
published PAM50 identifier (Parker et al. 2009) and genomic aberrations were 
identified using the SWITCHdna algorithm (Weigman et al.). 
 We were able to identify both previously observed large scale amplifications 
and deletions, and novel small-scale copy number aberrations, which we have 
highlighted a few selected examples here.  The Sum149 cell line has a previously 
identified micro-amplification in exon 2 of the PTEN gene (Saal et al. 2008), which 
we also clearly observed using our HD-aCGH platform (Figure 3.1a).  A number of 
other intra-genic aberrations were also detected, including a focal deletion in PTEN 
in a basal-like tumor (Figure 3.1b), an intra-genic deletion in RB1 in a basal-like 
tumor (Figure 3.1c), and a small RB1 amplification in a basal-like tumor (Figure 
3.1d). 
 To quantify micro-aberrations, we established a size definition of the 
smallest 25% of SWITCHdna identified aberrations in this dataset (<64 contiguous 
probes, <~15 kb).  The genomic landscape of the basal-like subtype exhibited many 
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of these micro-aberrations, as basal-like tumors have the highest incidence of these 
events (Table 3.1).  Basal-like tumors were seen to have the highest average number 
of micro-aberrations per sample, the highest median number of micro-aberrations 
per sample, and the greatest percentage of samples exhibiting micro-aberrations 
(Table 3.1). 
 The potential power of the high-density tiling array platform is shown in the 
example of the RB1 data (Figure 3.2 and 3.3).  Each identified micro- and macro-
aberration segment for this gene is plotted with the RB1 exons identified by each 
gray stripe, along with the location of each RB1 probe on the tiling array (green 
segments) and an earlier 109,000 feature single nucleotide polymorphism (SNP) 
platform (5 probes: orange dots).  The micro-aberration segments overlap with at 
most one genome-wide probe, and thus would have never been called a loss given 
how most aCGH programs call “changed segments”, which was the case for 
SWITCHdna. In addition, several macro-aberrations identified from the tiling array 
platform have minimal overlap with the 109K genome-wide probes.  49/94 samples 
had previously been assayed on the 109k SNP platform (Weigman et al.),  and the 
results of this overlap set for RB1 were compared directly in terms of CNA 
assignment agreement by SWITCHdna.  Again, focusing on the RB1 gene as our 
example case, we observed six copy number aberrations in these 49 samples by the 
tiling array for RB1 (Table 3.2).  Only two of these six CNA were detectable by the 
109k SNP array and these were the aberrations that spanned the whole gene.  The 
remaining four, all of which were intra-genic, were completely missed by the copy 
number segments generated from the whole-genome array (Table 3.2).  This is 
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illustrated in two example RB1 gene plots directly comparing the probes and 
segments from the high-density tiling array and the 109k SNP array (Figure 3.3).  
Copy Number Status Correlated with Expression 
 Beyond simply determining the frequency of micro-aberrations present 
within each gene or tumor, we wanted to assess whether the presence of micro-
aberrations would result in functional consequences.  We first assigned a copy 
number status for each gene and each sample (gross copy number gain, gross copy 
number loss, micro-amplification, or micro-deletion) and then within each gene, 
examined whether the corresponding gene expression was concordant with the 
type of genomic aberration observed, i.e. do micro-amplifications result in increased 
expression and/or do micro-deletions result in decreased expression of the involved 
gene.  We found similar rates of concordant expression between micro-aberrations 
and gross aberrations, with 30-40% of the genes showing 100% agreement between 
aberration type and gene expression, meaning that for these genes, every sample 
that displayed a micro-amplification in the gene also had greater than median 
expression of the gene and likewise every sample that had a micro-deletion in the 
gene had less than median expression of the gene.  Another 50-75% of the tested 
genes showed at least 50% concordance between aberration type and gene 
expression meaning at least half of the samples that displayed a copy number 
aberration had altered expression of the affected gene in the same direction as the 
CNA (Table 3.3).  These findings suggest that the micro-aberrations have functional 
effects upon gene expression similar to what is seen with larger scale CNA.  A 
number of genes displaying micro-aberrations also showed differential expression 
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of the involved gene when comparing the aberrant vs. non-aberrant groups by 
ANOVA (Figure 3.4).  ANOVA box plots are shown for the genes NUF2 (Figure 3.4a) 
and UBE2T (Figure 3.4b), where samples with micro-amplifications have 
significantly higher expression of the gene than those without micro-amplifications.  
Also shown are ZNF217 (Figure 3.4c), where samples with micro-deletions have 
lower expression of the gene than those without micro-deletions and SLC7A6 
(Figure 3.4d), where the samples with micro-deletions have higher expression than 
the samples that do not; we do note that the sample size is small in some cases, but 
the trends are present. 
Genomic Micro-amplification Causes Exon Skipping 
 We performed a closer examination of the micro-amplification of the PTEN 
gene in the SUM149 cell line, as it is a validated aberration that has now been shown 
by multiple groups.  Using mRNA-seq data, we assessed the expression of the PTEN 
gene on an exon level to determine the functional consequence of the DNA micro-
amplification.  For comparison, we also examined the data for the SUM102 cell line, 
which has no genomic alterations in PTEN.  The distribution of aligned reads for 
each exon is shown for each cell line (Figure 3.5).  In SUM149, there is a lack of PTEN 
gene expression starting from the middle of exon 2, which coincides with the 
location of the genomic DNA micro-amplification.  In comparison, the SUM102 cell 
line has aligned reads throughout the entirety of the PTEN gene, thus the micro-
amplification causes a loss of expression of all downstream exons. 
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The 5’ and Promoter Regions of Genes are Most Commonly Affected by Micro-
aberrations 
 In order to assess whether certain regions of genes were more commonly 
affected by micro-aberrations than others, we portioned each gene on the array into 
four quadrants: 5’ End, 5’ Middle, 3’ Middle, and 3’ End based upon a proportional 
splitting of each gene into 4 equal segments. For every micro-aberration instance 
(n=330), we noted the quadrants that it occupied, and then for each quadrant, 
determined what proportion of the total possible quadrants were affected by a 
micro-aberration event (Figure 3.6a).  We found that the 5’ end of the gene was 
disproportionately affected by micro-aberrations (~88% vs. <40%).  Additional 
refinement of the affected region was also performed and a large percentage of 
micro-aberrations also affected the promoter (defined as area upstream of the 
coding region) and 5’ UTR regions as well (80.6% and 79.7% respectively).  Of the 
aberrations whose area of effect was limited only to the 5’ End, the promoter region 
was affected at a higher rate than the 5’ UTR region (Figure 3.6b, 92.0% vs. 68.1%). 
Micro-aberration Frequency Associated with Poorer Survival 
 The survival outcomes of patients with varying levels of copy number 
aberrations were also assessed to determine if there was an association with 
outcomes.  We identified the number of copy number micro-aberrations per sample 
using our SWITCHdna criteria and rank-ordered the patients in terms of micro-
aberration frequency.  Patients were assigned to one of two groups depending on 
whether they were in the top 67% of microCNA or the bottom 33%.  Kaplan-Meier 
analysis was performed examining overall (Figure 3.7a) and relapse-free survival 
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(Figure 3.7b).  We saw that patients with the least genomic instability as assessed by 
SWITCHdna-called micro-aberrations had significantly better outcomes in terms of 
both overall and relapse-free survival.  
Cell Cycle Genes are Frequently Micro-aberrant 
 Lastly, we examined the frequency of micro-aberrations for each gene.  Here, 
we list the top 17 most micro-aberrant genes among those that were tested on this 
tiling array (Table 3.4a).  Gene Set Enrichment Analysis shows that genes exhibiting 
multiple micro-aberrations in our study were likely to be found in cell cycle-related 
pathways (Table 3.4b). 
Discussion 
 The previous discovery of focal aberrations within genes (Saal et al. 2008) 
using a high-density aCGH array, and the lack of description of such features in 
many whole-genome aCGH-based breast cancer studies (Weigman et al. ; 
Bergamaschi et al. 2006; Chin et al. 2006; Wood et al. 2007) suggests that these 
micro-aberrations may occur regularly in breast cancer genomes and that they 
simply have not yet been detected in previous studies.  To address this hypothesis, 
we assembled a dataset of 94 breast tumors and two breast cancer cell lines and 
tested them on a custom-designed aCGH tiling array; this array was targeted to 128 
gene panel focused on important cancer relevant genes (Supplemental Table 3.1) 
and previously identified basal-like cancer specific regions and genes (Fedele et al. ; 
Weigman et al. ; Bergamaschi et al. 2006; Johannsdottir et al. 2006). 
 By utilizing a previously tested segmentation and aberration calling 
algorithm called SWITCHdna (Weigman et al.), we analyzed the tiling array data and 
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proceeded to generate a numerical definition of a micro-aberration (Supplementary 
Table 3.2).  Essentially all of these micro-aberrations would be mostly undetectable 
using lower-resolution genome-wide platforms, as these segments would be 
covered by at most one probe on such arrays (Figure 3.2 and 3.3). An analysis of the 
frequency of micro-aberrations within our dataset samples showed that the basal-
like subtype had the most frequent occurrences of these events, mirroring their high 
overall genomic instability (Ding et al. ; Russnes et al. ; Bergamaschi et al. 2006; Chin 
et al. 2006; Van Loo et al. 2010); thus the presence of micro-aberrations did 
correlate with the presence of large aberrations.  Our data also shows that at least in 
some cases, these events have functional downstream consequences (Figure 3.4 and 
3.5, Table 3.3).  The finding of exon skipping at the point of the focal amplification in 
the PTEN gene in the SUM149 cell line is particularly interesting given the otherwise 
normal copy number.  The exact mechanism that induces this exon skipping is yet to 
be determined, but one can imagine that some aspect of the amplified DNA sequence 
results in an alteration to the pre-processed transcript that could cause early 
truncation or some sort of structural interference (Monaco et al. 1988; Liu et al. 
2001). 
 We did find that the initial 5’ end of these genes was the most heavily 
affected by micro-aberration events, specifically the promoter region of the gene 
(Figure 3.6).  It is unclear what leads to this predilection, but it does suggest that this 
specific portion of the gene may be more prone to genomic stress.  The involvement 
of the promoter region does suggest that this site of active transcriptional 
processing may lead to a structural genomic weakness that causes a predisposition 
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towards micro-aberrations.  This finding may also aid in explaining either the 
factors involved in the formation of micro-aberrations versus macro-aberrations or 
the possible downstream consequences of such events. 
 A limitation of our study is that we are currently unable to determine if any 
of these micro-aberrations are subtype specific.  If they are, this would 1) mirror 
whole genome study findings, and 2) potentially showcase an alternative means of 
gene disruption that unravels previously unexplained expression data.  As one 
example, RB1 dysfunction has been shown to be associated with the basal-like 
subtype (Jiang et al. 2010).  We have found in our own studies that RB1-LOH was 
highly correlated with gene expression patterns and patient outcomes while RB1 
protein expression on the same samples was not (Herschkowitz et al. 2008).  An 
intra-genic micro-aberration could potentially explain such cases, as the genetic 
abnormality may only affect a portion of the gene such that a protein is still 
produced and the majority of it intact, but it does not function properly.  Expanded 
studies with high-resolution platforms like whole genome sequencing will allow us 
to answer this question. 
 From a broader viewpoint, it stands to reason that other tumor types may 
also exhibit these types of events, but as yet they have not been widely described 
(2008).  However, similar intragenic deletions in RB1 and PTEN were recently 
described in melanoma cell lines (SKMEL-207, A2058, SKMEL-178 (Xing et al.)), 
suggesting that these types of micro-genomic events are present in other cancers 
and will reveal themselves using the newer methodologies.  It may also be true that 
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only certain cancer types display these aberrations though, which would suggest 
that there are mechanisms of genomic instability unique to these cancers. 
 In examining the specific genes on the tiling array that displayed micro-
aberrations, we noted that genes that were found in cell-cycle related pathways 
were particularly prone to these small-scale events.  Given that our panel of targeted 
genes was focused on cancer relevant genes, there was some inherent enrichment 
for this class of genes, but even within the background of genes on the array itself, 
there was a predilection for cell cycle genes.  Coupled with our finding of micro-
aberrations being localized to promoter regions, it may be that cell cycle genes are 
more prone to these events because of active transcriptional activity. 
 We were also able to make the observation that higher genomic instability in 
the form of micro-aberrations in our dataset was associated with poorer survival 
outcomes (Figure 3.7).  An overall high level of genomic instability has been found to 
associate with worse survival (Trope et al. 2000; Kristensen et al. 2003), and here 
we see that finding extended to micro-instability in our dataset.  There was 
however, a high concordance of overlap between patients that had many large scale 
changes and many micro-aberrations, and overall, patients with higher total 
numbers of CNA were associated with poorer outcomes (data not shown).  
Nonetheless, the same rank-ordering split that was performed on the micro-
aberrations did not result in identical findings for overall aberrations, suggesting 
that while there could be confounding of the micro-aberration survival findings by 
overall genomic instability, there may also be characteristics unique to the micro-
aberrations themselves.  Furthermore, the concordance between gross aberrations 
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and micro-aberrations suggests that there may be common mechanisms of genomic 
instability at play, which may yield insights into how micro-aberrations arise. 
Conclusions 
 In addition to exhibiting gross copy number changes, breast tumor genomes 
contain focal micro-aberrations as well when examined using high-resolution 
platforms.  These micro-aberrations occur within the background of global genomic 
instability and can have disruptive effects upon gene expression.  These micro-
events represent a potential means of mutagenesis in genes that have been 
otherwise determined to be normal in terms of gross copy number or SNV-based 
somatic mutations. Continued investigation into these events with improved tools 
will allow their increased detection and use as identifying characteristics of specific 
tumor. 
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3.3  Materials and Methods 
Breast Cancer Patient Dataset 
The dataset chosen for this study contained both gene expression and high-
density array comparative genomic hybridization (HD-aCGH) copy number data 
from a set of breast tumors from UNC “HD-UNC94” (n=94).  Additionally, the 
SUM102 and SUM149 breast cancer cell lines were also tested using these high-
density tiling arrays.  All samples were collected using IRB-approved protocols and 
all patients signed informed consent forms. Tumors in the dataset were assayed for 
gene expression patterns using Agilent DNA microarrays. Log2 ratio data was taken 
from the UNC Microarray Database (UMD), filtering for a lowess normalized 
intensity value of 10 or above for each channel, and 70% good data, and then used 
for further analyses. 
Classifying tumors for expression-based subtype classification 
The Lowess normalized R/G Log2 ratio data from the HD-UNC94 was used 
from the two different microarray platforms employed in this study (GPL5325 
Agilent UNC Perou Lab Homo sapiens 1X44K Custom Array, Agilent UNC Perou Lab 
Homo sapiens 1X244k Custom Array).  The datasets were then limited to the probes 
shared across both platforms.  After column standardization of both platforms 
(samples at N(0,1)), Distance Weighted Discrimination (DWD) (Benito et al. 2004) 
was used to remove platform bias prior to classification.  After correction, the R/G 
Log2 ratio data was collapsed (via averaging) from probes to HGNC gene symbols.  
The PAM50 gene set predictor(Parker et al. 2009) was used to assign subtypes to 
the tumors. 
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Tiling array design 
The custom HD-aCGH tiling platform was designed using Agilent’s E-array 
v5.0 online (https://earray.chem.agilent.com/earray/) software and built on the 
Human 244k Custom Oligo platform.  230,606 probes cover a total region of 45 Mb, 
which includes the full genomic sequence of the 128 genes of interest as well as the 
region 150 kb upstream and downstream of each gene (Supplementary Table 3.1) 
for an average resolution of 200bp.  Labeling and hybridization were performed 
according to manufacturer’s instructions using the Agilent Genomic DNA Labeling 
Kit PLUS.  A Human Genomic DNA Pool (Promega) was used as reference DNA.  
Microarrays were scanned on an Agilent DNA Microarray scanner (G2565CA) and 
the data uploaded to the University of North Carolina Microarray Database (UMD, 
www.genome.unc.edu). 
Identification of CNA and microCNA with SWITCHdna 
To determine regions of copy number aberrations (CNA), we utilized the 
SWITCHdna algorithm (Weigman et al.), focusing on individual genes.  For the 
purposes of this study, the analysis window was limited to the genomic region + 5kb 
upstream/downstream (Supplementary Table 3.1). In order to further filter the 
identified segments, we set the cutoff for the absolute value of the log2 ratio to be 
greater than 0.30 in order to reduce false positives.  After identifying all genomic 
segments of alteration with SWITCHdna, we analyzed the distribution of sizes of 
aberrant segments and established a cutoff of <64 contiguous SWITCH probes, or 
~<15kb as the definition of a micro-aberration, which equates to the smallest 25% 
of CNA in this dataset (Supplementary Table 3.2). 
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In order to identify the regions of genes, most commonly affected by micro-
aberrations, each gene was divided into four quadrants based on proportional 
splitting of each gene into four equal segments:  5’ End (promoter region, 5’UTR, 
beginning regions of gene), 5’ Middle (first ½ of gene), 3’ Middle (second ½ of gene), 
3’ End (end regions of gene, 3’ UTR, downstream region).  For every micro-
aberration instance, the affected quadrants were tallied and for each quadrant, the 
proportion of affected quadrants out of all possible quadrants was calculated.  
Similarly, each micro-aberration instance was assessed in terms of whether it 
encompassed the promoter or 5’ untranslated region (UTR) of each gene, with the 
promoter region defined as genomic space upstream of the transcription start site. 
mRNA-seq 
mRNA-seq was performed on RNA isolated from cell lines and tumors using 
the Qiagen RNeasy Mini Kit (Cat. No. 74104).  Library preparation was performed 
using the TruSeq RNA Sample Kit from Illumina (Cat. No. RS-930-2001) following 
the low throughput protocol detailed in the manufacturer's guidelines.  1x76bp 
nucleotide reads were generated using an Illumina GAII sequencer. 
Survival Analysis 
The patients in the dataset were rank ordered by total number of 
SWITCHdna-defined aberrations and micro-aberrations and separated in the top 
67% and bottom 33%.  Survival analyses were performed using the Kaplan-Meier 
test in R (R Development Core Team 2009). 
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3.5  Figures and Legends 
 
Figure 3.1:  Selected examples of intra-genic micro-aberrations. 
 
A) The previously identified PTEN exon 2 micro-amplification in SUM149 cell line 
DNA is observed, as is B) an intra-genic deletion also in PTEN in a basal-like tumor.  
Both C) focal deletion and D) amplification are seen in the RB1 gene, both in basal-
like tumors. 
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Figure 3.1 
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Figure 3.2:  Aberrations and probe locations for the RB1 gene. 
 
Each copy number aberrant segment called by SWITCHdna is plotted by its location 
within the RB1 gene.  Red segments indicate micro-aberrations and blue segments 
indicate macro-aberrations.  Exons are highlighted in grey bars.  The locations of the 
tiling array probes are indicated with green circles and the corresponding locations 
of probes from a previously used 109k genome-wide SNP platform are indicated 
with orange circles. 
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Figure 3.2 
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Figure 3.3:  Comparison of tiling array and 109k SNP platform generated 
SWITCHdna copy number segments for RB1. 
 
Two representative examples are shown illustrating the different detection 
thresholds achieved by the tiling array platform and the 109k SNP platform for CNA 
in RB1.  Exons are highlighted in grey bars.  The locations of the tiling array probes 
are indicated with crosses and the corresponding locations of the 109k genome-
wide SNP probes are indicated with orange circles.  SWITCHdna called segments for 
each platform are also shown with tiling array segments in blue and 109k platform 
segments in orange. 
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Figure 3.3 
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Figure 3.4:  The presence of micro-aberrations can result in differential 
expression by copy number status. 
 
Samples with micro-amplifications in A) NUF2 and B) UBE2T are associated with 
significantly higher expression of the gene than samples without these aberrations.  
Samples with micro-deletion in C) ZNF217 are associated with significantly lower 
expression of the gene than samples without these aberrations.  Samples with 
micro-deletion in D) SLC7A6 are associated with significantly higher expression of 
the gene than samples without these aberrations. 
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Figure 3.4 
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Figure 3.5:  A micro-amplification in PTEN in the SUM149 cell line results in 
lack of exon expression from the site of the aberration onwards. 
 
A) The distribution of mRNA-seq reads by exon is shown for the SUM149 and 
SUM102 cell lines.  B) For reference, the genomic space of the PTEN gene is shown, 
along with the copy number status across the PTEN gene in SUM149. 
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Figure 3.5 
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Figure 3.6:  Frequency that genomic quadrants are affected by micro-
aberrations. 
 
A) The percentage of total possible instances that a given genomic region is 
overlapped by a micro-aberration segment is displayed for each genomic quadrant 
(5’ End, 5’ Middle, 3’ Middle, 3’End) and the 5’ UTR and promoter regions.  B)  For 
the micro-aberrations that only affected the 5’ End region, the % of instances where 
it affected the promoter or 5’ UTR is listed. 
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Figure 3.6 
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Figure 3.7:  Higher levels of micro-aberrations are associated with worse 
survival outcomes. 
 
A) Kaplan-Meier plots for overall survival and B) relapse-free survival are shown for 
the patients in the tiling array datasets.  The patients were split into two groups, the 
top 67% in terms of total micro-aberrations versus the bottom 33%. 
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Figure 3.7 
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Table 3.1:  Copy number micro-aberrations by subtype. 
 
The mean and median numbers of micro-aberrations for samples within each 
subtype are shown, as is the percentage of samples within each subtype that 
exhibited any micro-aberrations. 
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Table 3.1 
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Table 3.2:  RB1 Copy Number Status on 49 samples from the tiling array and 
109k platforms. 
 
p-value determined by Fisher’s Exact Test. 
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Table 3.2 
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Table 3.3:  Percentage of genes exhibiting each class of micro-aberration with 
concordant gene expression. 
 
Results are shown for gross copy number gains, gross copy number losses, micro-
amplifications, and micro-deletions and frequency that genes are 100% concordant 
by gene expression or >=50% concordant by gene expression.  A concordant sample 
is one where a copy number gain or micro-amplification is accompanied by high 
expression of the affected gene or a copy number loss or micro-deletion is 
accompanied by low expression of the affected gene. 
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Table 3.4:  Listing of frequently micro-aberrant genes and pathway 
enrichment. 
 
A) The top 17 genes that displayed the most micro-aberrations are shown, along 
with the number of micro-aberrations seen within each gene.  B)  Results of a Gene 
Set Enrichment Analysis of the genes exhibiting more than one micro-aberration are 
displayed, showing an enrichment of cell-cycle related pathways. 
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Supplementary Table 3.1:  Gene list and tiling array coverage and analysis 
windows. 
 
List of the 128 genes on the tiling array with EntrezGene ID along with their 
genomic coordinates by NCBI build 36.1 (hg18) of the reference human genome.  
Coordinates are also provided showing the total coverage on the tiling array for 
each gene as well as the +/- 5kb analysis window that was used.  
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Supplementary Table 3.1 
 
Gene 
Name 
Entrez 
Gene 
ID 
Genomic Coordinates of 
Gene 
Gene 
Coverage 
Start 
Position 
Gene 
Coverage 
End 
Position 
Gene 
Analysis 
Start 
Position 
Gene 
Analysis 
End 
Position 
ABCC3 8714 chr17:46067227-46124062 45917227 46274062 46062227 46129062 
AGR2 10551 chr7:16811133-16797960 16961133 16647960 16816133 16792960 
AGR3 155465 chr7:16888138-16865555 17038138 16715555 16893138 16860555 
AKT3 10000 chr1:242073176-241718158 242223176 241568158 242078176 241713158 
AR 367 chrX:66680599-66860844 66530599 67010844 66675599 66865844 
AURKA 6790 chr20:54400758-54377852 54550758 54227852 54405758 54372852 
AVEN 57099 chr15:32118595-31945720 32268595 31795720 32123595 31940720 
BAG1 573 chr9:33254761-33242469 33404761 33092469 33259761 33237469 
BCL11A 53335 chr2:60634137-60531806 60784137 60381806 60639137 60526806 
BCL2 596 chr18:59137593-58941559 59287593 58791559 59142593 58936559 
BCL2A1 597 chr15:78050698-78040290 78200698 77890290 78055698 78035290 
BIRC5 332 chr17:73721872-73733311 73571872 73883311 73716872 73738311 
BRCA1 672 chr17:38530994-38449840 38680994 38299840 38535994 38444840 
BRCA2 675 chr13:31787617-31871809 31637617 32021809 31782617 31876809 
BTG3 10950 chr21:17907033-17887842 18057033 17737842 17912033 17882842 
BUB1 699 chr2:111152135-111111881 111302135 110961881 111157135 111106881 
CA12 771 chr15:61402783-61461128 61252783 61611128 61397783 61466128 
CCNB1 891 chr5:68498669-68509828 68348669 68659828 68493669 68514828 
CCND1 595 chr11:69165054-69178423 69015054 69328423 69160054 69183423 
CCNE1 898 chr19:34994741-35007059 34844741 35157059 34989741 35012059 
CDC20 991 chr1:43597213-43601461 43447213 43751461 43592213 43606461 
CDC6 990 chr17:35697672-35712939 35547672 35862939 35692672 35717939 
CDCA8 55143 chr1:37930746-37947978 37780746 38097978 37925746 37952978 
CDH1 999 chr16:67328696-67676586 67178696 67826586 67323696 67681586 
CDH3 1001 chr16:67236277-67290443 67086277 67440443 67231277 67295443 
CDK4 1019 chr12:56432431-56428270 56582431 56278270 56437431 56423270 
CDKN1B 1027 chr12:12761576-12766570 12611576 12916570 12756576 12771570 
CDKN2A 1029 chr9:21984490-21957751 22134490 21807751 21989490 21952751 
CDKN2B 1030 chr9:21999312-21992902 22149312 21842902 22004312 21987902 
CELSR1 9620 chr22:45311731-45135395 45461731 44985395 45316731 45130395 
CENPA 1058 chr2:26862386-26870961 26712386 27020961 26857386 26875961 
CENPF 1063 chr1:212843155-212904537 212693155 213054537 212838155 212909537 
CEP55 55165 chr10:95246399-95278839 95096399 95428839 95241399 95283839 
CFLAR 8837 chr2:201689135-201737260 201539135 201887260 201684135 201742260 
CKS2 1164 chr9:91115933-91121438 90965933 91271438 91110933 91126438 
CLDN4 1364 chr7:72883129-72884951 72733129 73034951 72878129 72889951 
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CLDN7 1366 chr17:7106519-7103946 7256519 6953946 7111519 7098946 
COX6C 1345 chr8:100975071-100959548 101125071 100809548 100980071 100954548 
CTPS 1503 chr1:41217594-41250822 41067594 41400822 41212594 41255822 
E2F1 1869 chr20:31737854-31727150 31887854 31577150 31742854 31722150 
EGFR 1956 chr7:55054219-55242525 54904219 55392525 55049219 55247525 
ELOVL5 60481 chr6:53321901-53240155 53471901 53090155 53326901 53235155 
EPCAM 4072 chr2:47449971-47467661 47299971 47617661 47444971 47472661 
ERBB2 2064 chr17:35097919-35138441 34947919 35288441 35092919 35143441 
ESR1 2099 chr6:152170379-152466099 152020379 152616099 152165379 152471099 
EXO1 9156 chr1:240078158-240119671 239928158 240269671 240073158 240124671 
FBP1 2203 chr9:96441624-96405236 96591624 96255236 96446624 96400236 
FGFR4 2264 chr5:176446527-176457733 176296527 176607733 176441527 176462733 
FIGF 2277 chrX:15312498-15273639 15462498 15123639 15317498 15268639 
FOXA1 3169 chr14:37134240-37128940 37284240 36978940 37139240 37123940 
FOXC1 2296 chr6:1555680-1559131 1405680 1709131 1550680 1564131 
FZD7 8324 chr2:202607555-202611405 202457555 202761405 202602555 202616405 
GALNT7 51809 chr4:174326479-174481693 174176479 174631693 174321479 174486693 
GATA3 2625 chr10:8136673-8157170 7986673 8307170 8131673 8162170 
GPR160 26996 chr3:171239397-171285878 171089397 171435878 171234397 171290878 
GRB7 2886 chr17:35147713-35157064 34997713 35307064 35142713 35162064 
GSTM1 2944 chr1:110031965-110037890 109881965 110187890 110026965 110042890 
GSTM3 2947 chr1:110084563-110078077 110234563 109928077 110089563 110073077 
ID4 3400 chr6:19945596-19948894 19795596 20098894 19940596 19953894 
IGF1 3479 chr12:101398454-101313806 101548454 101163806 101403454 101308806 
IGFBP2 3485 chr2:217206372-217237404 217056372 217387404 217201372 217242404 
KIF13B 23303 chr8:29176529-28980714 29326529 28830714 29181529 28975714 
KIF2C 11004 chr1:44978138-45006003 44828138 45156003 44973138 45011003 
KPNA1 3836 chr3:123716474-123623438 123866474 123473438 123721474 123618438 
KRAS 3845 chr12:25295121-25249447 25445121 25099447 25300121 25244447 
KRT14 3861 chr17:36996673-36992059 37146673 36842059 37001673 36987059 
KRT17 3872 chr17:37034335-37029220 37184335 36879220 37039335 37024220 
KRT18 3875 chr12:51628922-51632952 51478922 51782952 51623922 51637952 
KRT19 3880 chr17:36938167-36933395 37088167 36783395 36943167 36928395 
KRT5 3852 chr12:51200510-51194626 51350510 51044626 51205510 51189626 
KRT8 3856 chr12:51585127-51577238 51735127 51427238 51590127 51572238 
MAPT 4137 chr17:41327624-41461547 41177624 41611547 41322624 41466547 
MDM2 4193 chr12:67488247-67520481 67338247 67670481 67483247 67525481 
MIA 8190 chr19:45973140-45975235 45823140 46125235 45968140 45980235 
MKI67 4288 chr10:129814645-129784913 129964645 129634913 129819645 129779913 
MMP11 4320 chr22:22445036-22456503 22295036 22606503 22440036 22461503 
MYB 4602 chr6:135544146-135582003 135394146 135732003 135539146 135587003 
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MYBL2 4605 chr20:41729123-41778536 41579123 41928536 41724123 41783536 
MYC 4609 chr8:128817498-128554220 128967498 128404220 128822498 128549220 
NAT1 9 chr8:18111895-18125100 17961895 18275100 18106895 18130100 
NDC80 10403 chr18:2561605-2606629 2411605 2756629 2556605 2611629 
NUF2 83540 chr1:161558347-161592177 161408347 161742177 161553347 161597177 
ORC6L 23594 chr16:45281059-45289807 45131059 45439807 45276059 45294807 
P4HTM 54681 chr3:49002345-49019586 48852345 49169586 48997345 49024586 
PCNA 5111 chr20:5055268-5043599 5205268 4893599 5060268 5038599 
PGR 5241 chr11:100506465-100414313 100656465 100264313 100511465 100409313 
PHGDH 26227 chr1:120056033-120088361 119906033 120238361 120051033 120093361 
PIK3CA 5290 chr3:180349005-180435194 180199005 180585194 180344005 180440194 
PRC1 9055 chr15:89338808-89310272 89488808 89160272 89343808 89305272 
PTEN 5728 chr10:89613175-89718512 89463175 89868512 89608175 89723512 
PTTG1 9232 chr5:159781443-159788324 159631443 159938324 159776443 159793324 
RACGAP1 29127 chr12:48705488-48669212 48855488 48519212 48710488 48664212 
RAD17 5884 chr5:68700880-68746384 68550880 68896384 68695880 68751384 
RAD50 10111 chr5:131920529-132007498 131770529 132157498 131915529 132012498 
RAD51C 5889 chr17:54124962-54166691 53974962 54316691 54119962 54171691 
RAD51L1 5890 chr14:67356262-68132367 67206262 68282367 67351262 68137367 
RARA 5914 chr17:35718972-35767420 35568972 35917420 35713972 35772420 
RB1 5925 chr13:47775884-47954027 47625884 48104027 47770884 47959027 
REEP6 92840 chr19:1442165-1448924 1292165 1598924 1437165 1453924 
RRM2 6241 chr2:10180184-10188074 10030184 10338074 10175184 10193074 
S100A11 6282 chr1:150276135-150271606 150426135 150121606 150281135 150266606 
S100A8 6279 chr1:151630173-151629132 151780173 151479132 151635173 151624132 
S100A9 6280 chr1:151596954-151600127 151446954 151750127 151591954 151605127 
SCUBE2 57758 chr11:9069731-8998511 9219731 8848511 9074731 8993511 
SFRP1 6422 chr8:41286137-41238635 41436137 41088635 41291137 41233635 
SLC39A6 25800 chr18:31963355-31942492 32113355 31792492 31968355 31937492 
SLC40A1 30061 chr2:190153858-190133561 190303858 189983561 190158858 190128561 
SLC5A6 8884 chr2:27288575-27275962 27438575 27125962 27293575 27270962 
SLC7A6 9057 chr16:66855924-66893223 66705924 67043223 66850924 66898223 
SLC9A3 6550 chr5:577447-526425 727447 376425 582447 521425 
SPDEF 25803 chr6:34632069-34613558 34782069 34463558 34637069 34608558 
STK11 6794 chr19:1156798-1179434 1006798 1329434 1151798 1184434 
TAP1 6890 chr6:32929726-32920964 33079726 32770964 32934726 32915964 
TCF7L1 83439 chr2:85214245-85391016 85064245 85541016 85209245 85396016 
TK1 7083 chr17:73694880-73681755 73844880 73531755 73699880 73676755 
TOP2A 7153 chr17:35827695-35798321 35977695 35648321 35832695 35793321 
TP53 7157 chr17:7531642-7512445 7681642 7362445 7536642 7507445 
TP53BP2 7159 chr1:222100297-222034218 222250297 221884218 222105297 222029218 
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TSPAN13 27075 chr7:16759876-16790686 16609876 16940686 16754876 16795686 
TYMS 7298 chr18:647651-663492 497651 813492 642651 668492 
UBE2C 11065 chr20:43874662-43879003 43724662 44029003 43869662 43884003 
UBE2T 29089 chr1:200577707-200567408 200727707 200417408 200582707 200562408 
UIMC1 51720 chr5:176366049-176264612 176516049 176114612 176371049 176259612 
VEGFA 7422 chr6:43845931-43862202 43695931 44012202 43840931 43867202 
WIPF2 147179 chr17:35629100-35691965 35479100 35841965 35624100 35696965 
XBP1 7494 chr22:27526560-27520548 27676560 27370548 27531560 27515548 
YBX1 4904 chr1:42920653-42940607 42770653 43090607 42915653 42945607 
ZNF217 7764 chr20:51633043-51617017 51783043 51467017 51638043 51612017 
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Supplementary Table 3.2:  SWITCHdna segment size distribution. 
 
Histogram showing the distribution of SWITCHdna segments by size.
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Supplementary Table 3.2 
 
 
 
 
 
 
 
 
  
CHAPTER FOUR 
INPP4B IS A PUTATIVE IDENTIFYING AND PROGNOSTIC MARKER OF BASAL-LIKE 
BREAST TUMORS 
 
 
4.1  Introduction 
 Basal-like breast tumors have been shown to have frequent and specific copy 
number loss of INPP4B in multiple studies and low mRNA expression of this gene is 
seen in BBT.  INPP4B has been shown to be a key component of the PI3K signaling 
pathway and may act as a tumor suppressor that inhibits Akt activation, 
proliferation, and promotes apoptosis.  The association between INPP4B DNA, RNA, 
and protein expression, and breast cancer subtype is further examined in this study 
using a tumor slide dataset with associated gene expression and copy number data 
(UNC, n=125) and two different tissue microarrays, one with outcome data (SPECS-
TMA, n=106; UBC-TMA, n=318).  IHC staining was performed on the slide dataset 
and tissue microarrays to determine protein expression level.  It was shown that 
low INPP4B IHC staining levels were highly associated with BBT over other tumor 
subtypes and also that INPP4B copy number states, RNA gene expression, and 
protein expression were all strongly associated with one another.  Negative staining 
for cytoplasmic INPP4B was associated with significantly shorter mean relapse-free 
survival time on the UBC-TMA dataset.  Additionally, tumors which were able to 
achieve pathologic complete response had significantly lower RNA expression of 
INPP4B compared to those that had residual disease.  These findings indicate that 
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low INPP4B levels are specific to the basal-like subtype and track the known biology 
of BBT.  INPP4B may have utility as a clinical marker for BBT, and/or as a predictor 
for treatment response. 
The inherent heterogeneity of breast tumors shows that there are a host of 
oncogenes and tumor suppressors, which when dysregulated, lead to cancer-
promoting processes.  Previously, it has been shown that basal-like breast tumors 
(BBT) have a strong association with dysfunctional DNA repair pathways, 
illustrating one example of a defective cell pathway leading to tumor formation.  
However, one pathway alone is certainly insufficient to explain the development of 
all tumors; even within one specific subtype of breast cancer, it is not the case that 
all tumors of that subtype are only disrupted in a single manner. 
 One pathway of interest is the phosphoinositide 3-kinase (PI3K) signaling 
pathway, which promotes cell proliferation, survival, migration, angiogenesis, and 
genomic instability (Puc et al. 2005; Saal et al. 2005; Janzen and Scadden 2006; 
Baker 2007) (Figure 4.1).   This pathway has been shown to be dysregulated in a 
wide variety of cancers and mutations in key members of this pathway have been 
observed to induce neoplastic transformations in various model systems (Vivanco 
and Sawyers 2002; Engelman et al. 2006). 
Under normal cellular function, PI3K pathway activation occurs in response 
to extracellular stimuli, and increased production of the phosphoinositides, 
PtdIns(3,4,5)P3 and PtdIns(3,4)P2, occurs at the plasma membrane and leads to 
promotion of cell growth and cell survival pathways (Plas and Thompson 2005; 
Manning and Cantley 2007).  These phosphoinositides bind and activate several 
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downstream effectors, most notably the proto-oncogene Akt, and are necessary for 
full Akt activation in vivo (Franke et al. 1997; Scheid et al. 2002; Ma et al. 2008). 
 Downstream signaling of the PI3K pathway is normally countered by 
phosphatase degradation of PtdIns(3,4,5)P3. One such phosphatase is phosphatase 
and tensin homolog (PTEN), a 3-phosphotase and tumor suppressor that 
dephosphorylates PtdIns(3,4,5)P3 to form PtdIns(4,5)P2 (Ma et al. 2008).   Loss of 
PTEN expression or function is often seen in human cancers (Vazquez and Sellers 
2000) and murine models of PTEN deletion result in many tumor types (Di 
Cristofano et al. 1998; Kishimoto et al. 2003).  Furthermore, reduced PTEN is also 
seen to be associated with BBT (Weigman et al. ; Saal et al. 2008). 
Further processing of PI3K pathway phosphoinositides occur as 
PtdIns(4,5)P2 is hydrolyzed by inositol polyphosphate 4-phosphatases (Norris and 
Majerus 1994).  INPP4B is one such phosphatase and this gene has recently 
generated interest as it has been shown by us and others to be frequently and 
specifically deleted in BBT (Fedele et al. ; Weigman et al. ; Naylor et al. 2005; 
Bergamaschi et al. 2006; Chin et al. 2007).  Loss of INPP4B was also frequently 
associated with loss of PTEN in tumors (Fedele et al.).  Other observations also 
suggest an important role for INPP4B, such as the finding that shRNA targeting of 
the gene induces anchorage-independent growth in human mammary epithelial 
cells (HMEC) (Westbrook et al. 2005).  INPP4B knockdown is also shown to promote 
Akt activation, increased cell proliferation and tumor growth and low INPP4B 
protein expression is associated with poor outcomes in breast and ovarian cancers 
(Gewinner et al. 2009). 
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 Though a strong association has been shown between INPP4B loss and BBT, 
extensive analysis of INPP4B function within this subtype has not yet been 
performed.  Here, we have investigated INPP4B expression and function within 
breast tumor subtypes and determined the utility of differential INPP4B expression 
as a subtype and treatment response predictor. 
 
. 
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4.2  Results  
 In Chapter 2, we showed that in addition to being frequently and specifically 
lost on a copy number level in BBT, INPP4B also has significantly lower RNA 
expression when copy number loss is present (Figure 2.2) and of all the breast 
cancer subtypes, has the lowest expression in BBT (Figure 2.3F).  Here, we analyze 
the protein expression of INPP4B in our breast tumors using immunohistochemistry 
(IHC) and proceed to draw correlations with different aspects of breast cancer 
biology. IHC staining was performed on a set of 125 breast tumor slides and scored 
according to level of INPP4B staining (0-3 scale) (Figure 4.2).  The distribution of 
IHC scores was assessed across subtypes and we found that weak or absent INPP4B 
was much more likely to be found in ER-negative subtypes, and most frequently in 
basal-like samples, while high-intensity INPP4B staining was more prevalent in the 
two luminal subtypes (Table 1, p-value <.0001).  Furthermore, there was excellent 
correlation between the level of INPP4B protein expression, represented by IHC 
score, and the level of gene expression.  Each IHC staining level increase was 
associated with a commensurate increase in INPP4B gene expression (Figure 4.3). 
Finally, the association between INPP4B copy number status and INPP4B 
protein level was examined.  60 of the 125 IHC stained breast tumors had DNA copy 
number array data available and the copy number state of INPP4B was determined 
for this subset, with each sample being assigned a condition of gain, loss, or 
unchanged.  Within each of these copy number conditions, the tumors that were 
unchanged or gained for INPP4B on a DNA level were far more likely to have 
intermediate to strong staining for INPP4B by IHC.  Conversely, the breast tumors 
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that were determined to have copy number loss were significantly more likely to 
show weak or absent INPP4B protein levels (Table 4.2). 
Through collaboration with the Nielsen group at the University of British 
Columbia, we continued to determine the strength of the association between 
INPP4B levels and clinicopathologic characteristics by leveraging the use of tissue 
microarray (TMA) sets available at that institution.  Preliminary results from 
analysis of one of these TMAs (SPECS) (n=106), reveals a similar strong association 
with BBT as was seen in the set of 125 UNC slides.  Each tumor from the SPECS-TMA 
was classified as basal-like or non-basal and put into one of two categories based on 
INPP4B staining, <=5% of cells stained (low) or >5% of cells stained (high) (Table 
4.3).  Nearly all the non-basal samples exhibited high INPP4B staining (69/70, 
98.6%), while all but one of the samples that had low INPP4B staining was a basal-
like tumor (22/23, 95.7%). 
The ability of INPP4B expression to predict survival and therapeutic 
response was also assessed within available datasets.  A separate TMA with survival 
data was available to our collaborators from UBC (UBC) (n=318) and was utilized 
for this purpose.  Here, the samples were broken out by level of cytoplasmic staining 
intensity and median relapse-free survival times within each group were 
determined.  Although the magnitude of the difference is small, for those patients 
with negative staining for INPP4B, there was significantly shorter mean relapse-free 
survival time (Table 4.4). 
 In order to test the capability of INPP4B expression levels to predict 
pathologic complete response to neoadjuvant chemotherapy, the Hess et al. and 
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Hatzis et al. (Hatzis et al. ; Hess et al. 2006) combined dataset was employed.  Here, 
the samples were split into two groups, those that achieved pathologic complete 
response (pCR) and those that had residual disease (RD).  Within each group, the 
gene expression of INPP4B was determined for each sample, and the two groups 
were compared by ANOVA.  The ANOVA result showed that tumors that achieved 
pCR had significantly lower expression of INPP4B than those that did not (Figure 
4.4) 
Lastly, one other means by which we examined the relationship between 
INPP4B and breast cancer subtypes was to examine the level of INPP4B expression 
across a panel of breast cancer mouse models.  Similar to our findings on human 
breast tumors, we found that the basal-like tumor mouse models had the lowest 
mean expression for this gene, while models of other breast cancer subtypes had 
comparatively higher expression (Figure 4.5). 
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4.3  Discussion and Ongoing Studies 
 It has been seen that the different gene expression subtypes of breast cancer 
are often associated with distinct genetic alterations.  By understanding which 
subtype-specific genetic events are occurring in what types of pathways, we can 
potentially identify therapeutic targets to develop and pursue based on existing 
understanding of pathway function.  We expanded upon a previous study 
identifying basal-like specific regions of deletion and followed up on the finding that 
BBT have common loss of chromosome 4q, which contains the gene INPP4B (Fedele 
et al. ; Weigman et al. ; Gewinner et al. 2009).  We previously showed that in 
addition to being frequently and specifically copy-number lost for INPP4B, BBT also 
had the lowest average expression of the gene.  It was also seen that across all 
breast tumors, tumors with copy number loss of INPP4B had significantly lower 
expression, suggesting that the copy number deletions were functional (Weigman et 
al.).  In this study, we continue the examination between subtype and INPP4B 
expression, as well as more closely examining INPP4B expression on a protein level 
by IHC. 
 Utilizing INPP4B IHC staining and scoring by the level of staining, we found 
that BBT was also the subtype most strongly associated with absent or low INPP4B 
protein levels (Table 4.1).  These findings were observed not only on our UNC slide 
dataset, but also replicated on a separate TMA from UBC, showing that this is a 
robust finding (Table 4.3).  This same staining analysis is currently being performed 
on two, different larger TMAs (n=348, n=4000) and we anticipate that similar 
results will be observed. 
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Examination of INPP4B on a DNA, RNA, and protein level showed that there 
was great concordance in expression between these three levels as copy number 
lost samples were much more likely to have low INPP4B IHC staining and the level 
of IHC staining followed very closely in line with the level of RNA expression (Figure 
4.3, Table 4.2).  The combination of these factors points to the fact that low INPP4B 
expression appears to be an excellent marker for the basal-like subtype regardless 
of what methodology is used to determine expression level.  The strength of the 
association between IHC staining and BBT is particularly notable in terms of clinical 
utility as nucleic-acid analysis based laboratory testing is still in the minority 
compared to IHC staining (Netto et al. 2003). 
INPP4B expression levels also appear to have some functionality in terms of 
predicting survival times and therapeutic response.  We observed that those tumors 
with the lowest expression levels of this gene had the shortest relapse-free survival 
times (Table 4.4) and that patients who were able to achieve pCR had significantly 
lower expression of this gene compared to those who had residual disease (Figure 
4.4).  It is possible and likely that much of this is due simply to the association with 
the basal-like subtype, which also possesses these characteristics (Perou et al. 2000; 
Carey et al. 2007), but this does speak to the strength of its connection with this 
subtype. 
 When we examined INPP4B expression in a panel of mouse models of breast 
cancer, we saw that the basal-like models were the ones with the lowest expression 
of INPP4B, recapitulating the condition seen in humans (Figure 4.5).  This fact is 
encouraging as it appears these models may potentially share the same disruptions 
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in the PI3K pathway and can likely be used as a surrogate for human BBT in future 
studies, increasing our ability to unravel the mechanisms at play. 
Regarding the biology of INPP4B and the role it might play in basal-like 
formation, one potential model may tie together the defect in PI3K pathway 
signaling shown here along with previously discussed BBT associations with TP53 
and defective double-strand break repair.  A model previously proposed is that an 
initiating event occurs through TP53 disruption, through mutation or copy number 
loss, both of which are commonly seen in basal-like cancers.  This then allows the 
cell to lose BRCA1, which would otherwise be a lethal event (Evers and Jonkers 
2006), or, as we have proposed, lose other components of the BRCA1 repair 
pathway, eventually resulting in a BRCA1-dependent DSB repair defect.  Increased 
genomic instability occurs as a result of improper DNA repair function, which 
triggers disruption of other genes, such as components of the PI3K pathway.  PTEN 
is one such candidate for disruption, having been seen to be associated with BBT 
(Weigman et al. ; Saal et al. 2008); another potential candidate is INPP4B, as we have 
discussed here.  It has been proposed that BBTs may be addicted to aberrant PI3K 
pathway signaling (Weinstein 2002) and this cumulative model ties together many 
characteristics of BBT that explain how this could come about (Weinstein 2002). 
Further studies are required to more fully understand the role of INPP4B in 
BBT.  As mentioned, IHC staining is currently underway on a large TMA from our 
UBC collaborators (n=4000) that will give an even more complete view of this 
protein in breast cancer.  This set will also come with more robust clinical outcomes 
data and more associations can be drawn from this analysis, potentially including a 
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new prognostic signature derived from INPP4B.  Functional studies are also 
underway to reconstitute INPP4B expression in basal-like tumor cell lines of both 
mouse and human origin.  The aim of these studies is to more robustly determine 
the physiologic role of these genes in a cancer background and identify a 
transcriptional program that can be mined for a genetic signature and potential 
therapeutic targets. 
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4.4  Materials and Methods 
Breast Cancer Patient Datasets 
Three patient datasets were used in this study, one UNC tumor slide set 
(n=125) and two different TMAs from the Nielsen group, SPECS (n=106) and UBC 
(n=318).  The UNC set contained gene expression and DNA copy number microarray 
data, while the UBC set had clinical outcomes data.  For pCR vs. RD analyses, the 
previously published Hess et al. (Hess et al. 2006) and Hatzis et al. (Hatzis et al.) 
datasets were combined and utilized (n=588). 
Survival and Response Analysis 
Each patient tumor in the UBC-TMA was classified into one of four groups 
based on level of IHC staining (negative, low, moderate, strong).  Survival analyses 
were performed using the Kaplan-Meier test.  For association with pCR, the patients 
were split into those that achieved pCR and those that had residual disease and the 
expression of INPP4B was compared between those two groups by ANOVA test. 
Tumor subtype classification 
For all tumors, the Lowess normalized R/G Log2 ratio data were median 
centered prior to collapsing (via averaging) from probes to HGNC gene symbols.  
The PAM50 gene set predictor (Parker et al. 2009) was then used to assign subtypes 
to the tumors in the UNC slide dataset and the UBC TMAs.  For the UNC slide set, the 
Claudin-low predictor(Prat et al.) was also applied. 
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Copy Number Status Assignment 
To determine the INPP4B copy number state of tumors on the UNC slide 
dataset, we used aCGH data from previously performed studies and applied the 
SWITCHdna algorithm (Weigman et al.). 
Immunohistochemistry  
Formalin-fixed, paraffin-embedded tissue sections (~5m) were processed 
using standard immunostaining methods. Following deparaffinization in xylenes, 
slides were rehydrated through a graded series of alcohol and rinsed in phosphate 
buffered saline. Endogenous peroxidase activity was blocked with 3% hydrogen 
peroxidase. Samples were steamed for antigen retrieval with 10 mM citrate buffer 
(pH 6.0) for 30 minutes. Slides were then incubated for 20 minutes with diluted 
normal blocking serum. The sections were incubated for 60 minutes at room 
temperature with primary antibody to INPP4B (Epitomics 2512-1 1:5000). The 
slides were incubated for 45 minutes with diluted biotinylated secondary antibody 
(1:250 dilution) and 30 minutes with Vectastain Elite 102 ABC reagent (Vector 
Laboratories). Sections were incubated in peroxidase substrate solution for 
visualization.  Slides were counterstained with hematoxylin and examined by light 
microscopy. Tumor immunoreactivity was scored 0=negative, 1=weak positive, 
2=intermediate positive, and 3=strong positive. 
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4.5  Figures and Legends 
 
Figure 4.1:  PI3K Pathway. 
 
The PI3K signaling pathway is illustrated.  Under normal circumstances, receptor 
stimulation leads to the formation of PI(3,4,5)P3 and PI(3,4)P2 from PI3K activity.  
These phospholipids induce Akt activation and increased cell proliferation, survival, 
and migration.  PI3K signaling is terminated through the activity of PTEN, which 
hydrolyzes PI(3,4,5)P3 to PI(4,5)P2, or INPP4B, which converts PI(3,4)P2 to PI(3)P.  
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Figure 4.1 
 
 
 
Figure adapted from Gewinner et al., Cancer Cell (2009) 
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Figure 4.2:  INPP4B IHC Staining Scoring Levels. 
 
Representative images of each level of INPP4B IHC scoring is shown (IHC Score 0-3).  
IHC Score 0:  no staining or less than 5% cells stained; IHC Score 1: weak staining; 
IHC Score 2:  intermediate staining; IHC Score 3:  strong staining. 
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Figure 4.2 
 
IHC Score 0     IHC Score 1 
 
 
IHC Score 2     IHC Score 3 
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Figure 4.3:  INPP4B Expression by INPP4B IHC Score. 
 
Tumors from the UNC slide dataset (n=125) are grouped by their INPP4B IHC score 
and INPP4B expression is determined for each sample.  p-value determined by 
ANOVA test.
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Figure 4.3 
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Figure 4.4:  INPP4B Expression by pCR Status. 
 
Tumor samples from the Hess et al. (Hess et al. 2006) and Hatzis et al. (Hatzis et al.) 
combined dataset are separated into groups by those with a pathologic complete 
response (pCR) or residual disease (RD) and INPP4B expression is evaluated for 
each sample within each group.  p-value determined by ANOVA test. 
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Figure 4.4 
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Figure 4.5:  INPP4B Expression across a panel of murine breast cancer models. 
 
INPP4B expression level was assessed across a panel of mouse breast cancer 
models.  Each mouse tumor was grouped by model and INPP4B expression levels 
were assessed within each group. p-value determined by ANOVA test. 
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Figure 4.5 
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Table 4.1:  INPP4B IHC Score by Subtype. 
 
Each sample from the UNC slide dataset is displayed based on its classification by 
PAM50+Claudin subtype and IHC score.  p-value determined by Fisher’s Exact test. 
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Table 4.1 
 
 
  
IHC Score (0-3) 
 
  
0 1 2 3 Total 
Su
b
ty
p
e 
Basal 7 12 2 4 25 
Claudin 3 2 7 5 17 
Her2 1 5 5 2 13 
LumA 1 0 7 23 31 
LumB 0 4 7 16 27 
Normal 0 1 1 3 5 
Unassigned 0 3 2 2 7 
 
Total 12 27 31 55 125 
       
     
p-value < .0001 
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Table 4.2:  INPP4B Copy Number State by IHC Score. 
 
For the 60 tumors on the UNC slide dataset with available copy number data, each 
was grouped based on its copy number status (gain, lost, unchanged) and IHC 
scoring level (low:  0-1, or high: 2-3).  The percentage of tumors within each copy 
number state that had low or high IHC staining is displayed in parentheses.  p-value 
determined by Fisher’s Exact Test. 
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Table 4.2 
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Table 4.3:  SPECS TMA INPP4B IHC Staining by Subtype. 
 
The tumors on the SPECS-TMA were classified by subtype in terms of basal or not-
basal and grouped according to subtype and IHC staining level (low:  <=5% of tumor 
cells, or high: >5% of tumor cells).  The percentage of tumors within each subtype 
with low or high IHC staining is displayed. 
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Table 4.3 
 
 
 
 
INPP4B Basal vs. Non-Basal Crosstabulation 
  
Basal vs. Non-Basal 
Total Non-Basal Basal 
INPP4B 
<=5% 
Tumor Cells Count 1 22 23 
    
% Within Basal 
vs. Non-Basal 1.40% 61.10% 21.70% 
  
>5% Tumor 
Cells Count 69 14 83 
    
% Within Basal 
vs. Non-Basal 98.60% 38.90% 78.30% 
Total 
 
Count 70 36 106 
    
% Within Basal 
vs. Non-Basal 100% 100% 100% 
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Table 4.4:  Mean Relapse-Free Survival Time by level of cytoplasmic INPP4B 
intensity. 
 
Tumors on the UBC-TMA were split into four groups based on INPP4B cytoplasmic 
staining intensity level (negative, low, moderate, strong) and mean+/-95% 
confidence interval relapse-free survival times are displayed for each group. 
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Table 4.4 
 
 
 
 
 
 
 
 
 
 
 
  
CHAPTER FIVE 
DISCUSSION 
 
 
5.1  Summary of Findings 
 Since the discovery of the breast tumor intrinsic subtypes, our understanding 
of the molecular underpinnings of breast cancer has steadily increased and this has 
allowed more informed identification and treatment of the disease.  To date, there 
have been at least six different breast cancer subtypes identified, luminal A, luminal 
B, normal breast-like, HER-enriched, claudin-low, and basal-like (Perou et al. 2000; 
Sorlie et al. 2001; Sorlie et al. 2003; Hu et al. 2006; Herschkowitz et al. 2007; Parker 
et al. 2009), each with biological and clinical relevance, as each subtype has unique 
clinical outcomes and response to treatment (Carey et al. 2006; Fan et al. 2006; 
Carey et al. 2007; Hoadley et al. 2007).  These subtypes are defined both by the 
genes they express, such as ESR1 (luminal) and HER2 (HER2-enriched), and the 
genes they do not express, such as claudins 3, 4, and 7 (claudin-low).  As technology 
continues to advance and new high-throughput technologies are developed and 
employed, the ability to study these cancers steadily improves.  Already, it has been 
shown that breast cancers have distinct characteristics beyond expression profiles, 
including that they are distinct on a DNA copy number level as well (Russnes et al. ; 
Weigman et al. ; Jonsson et al. 2005; Bergamaschi et al. 2006; Haverty et al. 2008).  
There is a persistent need to further elucidate the biological basis for breast tumor 
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development as this disease continues to be a leading killer of women.  The basal-
like breast tumors, the focus of this work, are of particular importance, as they 
would be considered the 4th leading cancer killer of women if viewed as an 
individual disease. 
 
 In this work, I investigate the genomic landscape of BBT and examine basal-
like specific areas of copy number aberration in order to define unique basal-like 
characteristics, and identify factors that contribute to its genomic instability 
phenotype.  The main findings are summarized below: 
Basal-like Breast Cancer DNA Copy Number Losses Identify Genes Involved in Genomic 
Instability, Response to Therapy and Patient Survival 
1. Basal-like breast tumors exhibit frequent aberrations in copy number 
landscape, with the loss of regions that contain BRCA1-dependent DNA 
repair pathway genes. 
2. Many DNA repair pathway genes that show copy number loss also exhibit 
low gene expression levels. 
3. BRCA1 pathway genes located on chromosome 5q (RAD17, RAD50, RAP80) 
are frequently lost in unison and rarely individually. 
4. Low expression of DNA repair genes on chromosome 5q (RAD17, RAD50, 
RAP80) is associated with poor survival. 
5. Gene knockdown of RAD17 and/or RAD50 reduces the ability of the cell to 
form BRCA1 foci in response to DNA damage. 
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6. Disruption of the BRCA1 pathway by gene knockdown increased sensitivity 
to DNA damaging agents. 
 
Micro-scale Genomic Copy Number Aberrations as Another Means of Mutagenesis in 
Breast Cancer 
1. Breast tumors have a significant number of previously undetectable copy 
number micro-aberration events that are detectable by a high-resolution 
tiling copy number array. 
2. Micro-aberrations are most commonly observed in basal-like breast tumors. 
3. Copy number micro-aberrations can have functional consequences on the 
exon-level RNA expression of the aberrant gene. 
4. Exon skipping is one observed functional consequence of micro-aberrations 
on gene expression. 
5. Copy number micro-aberrations are disproportionately located in the 
promoter regions of genes. 
6. Copy number micro-aberrations are enriched in cell-cycle related genes. 
7. A high frequency of copy number micro-aberrations is associated with poor 
overall survival. 
 
INPP4B is a Putative Identifying and Prognostic Marker of Basal-like Breast Tumors 
1. Basal-like breast tumors have frequent copy number loss of INPP4B, low RNA 
expression of INPP4B, and low protein expression of INPP4B. 
2. INPP4B levels are highly concordant on the DNA, RNA, and protein levels. 
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3. Low expression of INPP4B is associated with the ability to achieve a 
pathologic complete response, but also shorter relapse-free survival time. 
4. Mouse models of basal-like breast cancer have the lowest average expression 
of INPP4B across a panel of breast cancer mouse models. 
5. Low expression of INPP4B may be a biomarker of responsiveness to PIK3CA 
inhibitors. 
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5.2  Clinical Relevance 
Breast Cancer Burden in the United States and North Carolina 
At present, ~12% of women will develop invasive breast cancer during the 
course of her lifetime, with an estimated 230,480 new cases in 2011 in the United 
States, and another 57,650 new non-invasive cases.  This represents the most 
commonly diagnosed form of cancer in women, excluding skin cancer, accounting 
for ~30% of all cancers in women.  39,520 women were expected to die from their 
disease in the same year.  Though death rates have been decreasing since 1990, 
notably in women under age 50, breast cancer death rates are still higher than any 
other type of cancer for women, aside from lung cancer.  Additionally, there are 
more than 2.6 million breast cancer survivors in the US (Statistics courtesty 
breastcancer.org). 
Breast cancer in the State of North Carolina poses significant challenges to 
the health care system as there were 8,553 new cases in 2009 and another 8,597 
new cases projected for 2011.  In addition, breast cancer as a whole is a leading 
cancer killer of NC women and if BBT were to be treated as a unique disease 
separate from other breast cancers, it would represent the fourth leading cause of 
cancer deaths among women. 
The research described here give us a greater understanding of how BBT 
arise. More importantly, these experiments help to highlight potential therapeutic 
targets, something that has been critically lacking for this subgroup so far. Currently, 
treatment regimens for basal-like breast tumors are limited to cytotoxic 
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chemotherapies, which have severe side effects; thus, continued advancements to 
improve both clinical outcome and treatment tolerability are still needed. 
Potentially Targetable Molecular Pathways Associated with Basal-like Breast Cancer 
 Identifying molecular pathways that drive basal-like breast cancers, and that 
may also explain their development provides an avenue through which to pursue 
potentially druggable targets for this disease.  Two such pathways that show 
promise as basal-like involved targets that have been described in this work are the 
DSB DNA repair pathway and the PI3K signaling pathway. 
This research provides preclinical support for clinical trials using PARP 
inhibitors such as the one titled “A Phase II Study of the PARP Inhibitor, INIPARIB 
(BSI-201), in Combination With Chemotherapy to Treat Triple Negative Breast 
Cancer Brain Metastasis”, which is currently being run here at UNC.  Successful 
completion of this trial, among the first of the PARP inhibitor trials, could provide 
improvements in the ability to provide care to women suffering from BBT and result 
in significant clinical benefits.  Other means of exploiting the synthetic lethality 
conferred by DNA repair defects could also prove promising. 
The PI3K signaling pathway is also a proposed therapeutic target in a range 
of cancers and there are currently a number of phase I–II clinical trials in progress 
investigating the efficacy of PI3K inhibitors.  Indeed, it has been proposed that the 
DSB repair defects of BBT may precipitate PI3K signaling pathway dysfunction 
through genetic disruption of PTEN (Saal et al. 2008), suggesting that therapy 
targeted to this pathway may be an effective means to treat some sporadic and 
hereditary breast cancers.  The level of INPP4B expression may also prove useful as 
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in cell lines, loss of INPP4B sensitized cells to PIK3CA inhibitors. Thus, loss of 
INPP4B, or simply being a Basal-like tumor may be a marker in predicting the 
patients that will respond to PIK3CA inhibitors. 
Improving Ability to Differentiate Basal-like Breast Cancer 
An increase in the ability to differentiate more clearly between the known 
breast cancer subtypes is also clinically relevant, given what is already known about 
prognostic associations with each subtype.  By knowing that a given cancer is of a 
more aggressive form, this potentially informs the clinician to pursue more 
aggressive therapy at the start; conversely, by knowing that a given cancer is 
unlikely to respond further to aggressive therapy, it allows the patient to be spared 
certain unwanted side effects of treatment.  Clear knowledge of the type of breast 
cancer one has also allows the patient to be more informed of one’s disease. 
In this work, we identified a number of novel basal-like specific features from 
copy number analyses.  Indeed, we find that loss of the 5q genes (RAD17, RAD50, 
RAP80) is very specific (>90%) at predicting BBT over other subtypes.  When 
coupled with gain of chromosome 10p, it becomes even more specific for BBT, and 
these factors could allow the clinician to be confident in the diagnosis.  INPP4B loss 
was also determined to be a basal-specific feature and with our collaborators at 
UBC, it was found to possess the best combination of sensitivity (61%) and 
specificity (99%) of any single marker they surveyed for identifying BBTs using IHC. 
Continued discovery of such factors and improved understanding of the differences 
between the subtypes helps improve diagnostic power. 
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5.3  Long-term Directions 
Identify Other Subtype-specific Markers with New Datasets and Tools 
 More data regarding breast cancer is being generated daily, whether this 
occurs through samples collected in new datasets, or analyses being performed 
using new technologies.  Though we identified a number of novel findings of 
functional significance in this work, the drive to progress certainly does not cease.   
A collaborative effort that has been underway in recent years is The Cancer 
Genome Atlas (TCGA), which aims to fully analyze a large number of cancers on 
multiple levels, including full genome sequencing, mRNA-sequencing, methylation, 
and protein expression.  One cancer type to be examined is breast cancer and 
already we have seen a number of the findings in this work recapitulated in this 
large dataset; importantly, the loss of 4q and 5q as basal-like subtype specific events 
was rediscovered on TCGA breast data (C.Perou, personal communications).  The 
expanded information available through this pursuit allows us to more fully 
examine our findings and draw more complete conclusions that tie in information 
from this cancer on all levels.  For example, we put forth the hypothesis that all BBT 
may have some form of BRCA1 pathway dysfunction, but have been limited to 
identifying the dysfunction only on a DNA and RNA level.  The TCGA allows us to 
study these tumors on all levels and see other forms of inactivation to test this 
hypothesis which have simply not been available to us previously. 
Another continued goal is to develop a greater understanding of the nature of 
micro-instability within breast cancers and other tumors.  Though we characterized 
them in Chapter 3, we are as yet unable to describe them fully on a sequence level 
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and explain the exact nature of certain micro-amplifications.  This represents an 
area of ongoing study and indeed the full-genome sequencing information from the 
TCGA may be one means to answer this question. 
Continued Analysis of Basal-like Specific Targets 
 Aside from the basal-like specific regions of aberration discussed in this 
work, there are a number of other areas of both gain and loss identified for this 
subtype that may also contain promising candidates for study.  Although in Chapter 
2, we examined the patterns of loss and functional effects of three BRCA1-
dependent DNA repair pathway genes located on chromosome 5q, we did in fact 
identify other components of this pathway in our initial analyses.  A few examples 
are RAD51, RAD51B, and RAD51C, located on chromosome 15q15, 14q12, and 17q23 
respectively.  We attempted to prioritize what we believed to be the most important 
players, but these other candidates may also make key contributions to the genomic 
instability phenotype of BBT. 
 Another potentially promising region to further investigate is an amplified 
region on chromosome 10p also found to be basal-specific.  This region notably 
contained the genes MAP3K8, ZEB1, and FAM107B.  Though this region was not 
robustly investigated in the manner in which chromosome 5q11-35 was, the fact 
that it is gained instead of lost is potentially useful clinically as it is currently easier 
to inhibit an overactive target than replace a missing factor.  MAP3K8, in particular, 
is a kinase that could be effectively targeted if it does turn out to be a critical driver 
of this particular amplicon. 
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 Beyond the two regions highlighted here, there are still several regions of 
aberration that have not been extensively examined.  There may still be important 
targets yet to be discovered that drive BBT etiology that will reveal themselves with 
more detailed analyses.  The need and potential for continued improvements in BBT 
treatment means that this remains an area of active research.  
Identify Importance of Other Subtype-specific Regions of Aberration 
 Though the focus of this work was on the basal-like subtype due to its poor 
clinical prognosis and paucity of treatment options, we do still face challenges in 
treating the other breast cancer subtypes.  Even though luminal breast cancers have 
relatively good outcomes compared to other breast subtypes, they actually result in 
the highest number of total deaths due simply to the fact that most breast cancers 
are luminal breast cancers (O'Brien et al.).  Thus, the other subtypes should not 
simply be ignored as there is much benefit to be derived from a greater 
understanding of disease processes and treatment improvements for those groups 
as well. 
 We focused on basal-like specific aberrations here, but the Luminal A, 
Luminal B, and Her2-enriched subtypes all displayed specific regions of aberration 
as well.  Though initial analyses did not expose any obvious targets within these 
regions, useful findings may still be derived from mining this data.  It would be of 
great utility if relevant targets could be found within every subtype that help both 
uniquely identify the subtype and play critical roles in their development that were 
exploitable for therapy. 
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5.4  Concluding Remarks 
In summary, the work described here examines the role of genomic 
instability in basal-like breast tumors (BBT), primarily in the context of the BRCA1-
dependent DNA repair pathway.  The analyses identified several regions of 
aberration specific to BBT, and associated functional studies showed possible effects 
of these disruptions that may explain their DNA repair defect and other 
contributions to overall genomic instability.  These findings provide insights into 
BBT biology and lay the groundwork for many future studies. 
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